Catalyst Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Catalyst Pharmaceuticals Inc together

Penke I guess you are interested in Catalyst Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Catalyst Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Catalyst Pharmaceuticals Inc

I send you an email if I find something interesting about Catalyst Pharmaceuticals Inc.

Quick analysis of Catalyst Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Catalyst Pharmaceuticals Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

0.0%

What is your share worth?

Current worth

$3.29

Expected worth in 1 year

$4.03

How sure are you?

55.0%

+ What do you gain per year?

Total Gains per Share

$0.74

Return On Investment

4.9%

For what price can you sell your share?

Current Price per Share

$15.12

Expected price per share

$12.27 - $17.43

How sure are you?

50%

1. Valuation of Catalyst Pharmaceuticals Inc (5 min.)

Live pricePrice per Share (EOD)

$15.12

Book Value per Share

$3.29

Intrinsic Value Per Share

$-119.60 - $53.38

Total Value Per Share

$-116.31 - $56.67

My calculation of the intrinsic value of Catalyst Pharmaceuticals Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-4.07) 3Y: ($0.14) TTM: ($0.06)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.01) 3Y: ($0.07) TTM: ($-0.04)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-15.64	$1.27	$-16.19 - $1.72
2	$-30.32	$3.59	$-16.11 - $2.87
3	$-44.11	$6.91	$-16.03 - $4.03
4	$-57.05	$11.18	$-15.95 - $5.18
5	$-69.19	$16.32	$-15.87 - $6.33
6	$-80.59	$22.28	$-15.79 - $7.48
7	$-91.29	$29.02	$-15.71 - $8.63
8	$-101.33	$36.48	$-15.63 - $9.78
9	$-110.75	$44.61	$-15.55 - $10.93
10	$-119.60	$53.38	$-15.47 - $12.08

2. Growth of Catalyst Pharmaceuticals Inc (5 min.)

Is Catalyst Pharmaceuticals Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$387.8m	$257.9m	$103.4m	28.6%

How much money is Catalyst Pharmaceuticals Inc making?

	Current year	Previous year	Grow	Grow %
Making money	$17.8m	$20.7m	-$2.9m	-16.3%
Net Profit Margin	18.5%	38.3%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Catalyst Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#144 / 1010

Most Revenue
#98 / 1010

Most Profit
#76 / 1010

Most Efficient
#84 / 1010

What can you expect buying and holding a share of Catalyst Pharmaceuticals Inc? (5 min.)

Welcome investor! Catalyst Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Catalyst Pharmaceuticals Inc.

What can you expect buying and holding a share of Catalyst Pharmaceuticals Inc?

First you should know what it really means to hold a share of Catalyst Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Catalyst Pharmaceuticals Inc is $15.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Catalyst Pharmaceuticals Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Catalyst Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.29. Based on the TTM, the Book Value Change Per Share is $0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $0.20 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Catalyst Pharmaceuticals Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	0.30	2.0%	0.15	1.0%	0.18	1.2%	0.13	0.8%	0.04	0.3%
Usd Book Value Change Per Share	0.33	2.2%	0.19	1.2%	0.20	1.3%	0.14	0.9%	0.08	0.5%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	0.33	2.2%	0.19	1.2%	0.20	1.3%	0.14	0.9%	0.08	0.5%
Usd Price Per Share	16.81	-	14.63	-	11.68	-	8.02	-	5.30	-
Price to Earnings Ratio	14.22	-	7.51	-	16.53	-	0.12	-	-7.74	-
Price-to-Total Gains Ratio	50.37	-	23.92	-	59.24	-	120.17	-	21.91	-
Price to Book Ratio	5.11	-	4.78	-	5.19	-	4.98	-	5.78	-
Price-to-Total Gains Ratio	50.37	-	23.92	-	59.24	-	120.17	-	21.91	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	15.12
Number of shares	66

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	0.19	0.14
Usd Total Gains Per Share	0.19	0.14
Gains per Quarter (66 shares)	12.24	9.44
Gains per Year (66 shares)	48.98	37.75

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	49	39	0	38	28
2	0	98	88	0	76	66
3	0	147	137	0	113	104
4	0	196	186	0	151	142
5	0	245	235	0	189	180
6	0	294	284	0	227	218
7	0	343	333	0	264	256
8	0	392	382	0	302	294
9	0	441	431	0	340	332
10	0	490	480	0	378	370

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	3.0	1.0	0.0	75.0%	11.0	1.0	0.0	91.7%	18.0	2.0	0.0	90.0%	18.0	22.0	0.0	45.0%	18.0	55.0	0.0	24.7%
Book Value Change Per Share	3.0	1.0	0.0	75.0%	11.0	1.0	0.0	91.7%	19.0	1.0	0.0	95.0%	22.0	18.0	0.0	55.0%	34.0	37.0	2.0	46.6%
Dividend per Share	0.0	0.0	4.0	0.0%	0.0	0.0	12.0	0.0%	0.0	0.0	20.0	0.0%	0.0	0.0	40.0	0.0%	0.0	0.0	73.0	0.0%
Total Gains per Share	3.0	1.0	0.0	75.0%	11.0	1.0	0.0	91.7%	19.0	1.0	0.0	95.0%	22.0	18.0	0.0	55.0%	34.0	37.0	2.0	46.6%

Fundamentals of Catalyst Pharmaceuticals Inc

About Catalyst Pharmaceuticals Inc

https://www.catalystpharma.com
Biotechnology
167
355 Alhambra Circle, Coral Gables, FL, United States, 33134
Google Maps Bing Maps

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Fundamental data was last updated by Penke on 2024-04-11 04:52:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Catalyst Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Catalyst Pharmaceuticals Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
A Net Profit Margin of 31.5% means that $0.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Catalyst Pharmaceuticals Inc:

The MRQ is 31.5%. The company is making a huge profit. +2
The TTM is 18.5%. The company is making a huge profit. +2

Trends

Current period		Compared to		+/-
MRQ	31.5%	TTM	18.5%	+13.0%
TTM	18.5%	YOY	38.3%	-19.7%
TTM	18.5%	5Y	34.8%	-16.3%
5Y	34.8%	10Y	-55.1%	+89.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	31.5%	-200.1%	+231.6%
TTM	18.5%	-216.8%	+235.3%
YOY	38.3%	-288.3%	+326.6%
5Y	34.8%	-449.1%	+483.9%
10Y	-55.1%	-605.5%	+550.4%

Measures how much net profit Catalyst Pharmaceuticals Inc earns for each $1 of revenue.

Revenue is the amount of profit Catalyst Pharmaceuticals Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Catalyst Pharmaceuticals Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Catalyst Pharmaceuticals Inc makes more profit. This shows the investor how efficiently Catalyst Pharmaceuticals Inc is operating in general and compared to other companies in the same industry. Catalyst Pharmaceuticals Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Catalyst Pharmaceuticals Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Catalyst Pharmaceuticals Inc is 0.32. This means that Catalyst Pharmaceuticals Inc earned $0.32 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -200.1%.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Catalyst Pharmaceuticals Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Catalyst Pharmaceuticals Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Catalyst Pharmaceuticals Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Catalyst Pharmaceuticals Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Catalyst Pharmaceuticals Inc = 34,844
Total revenue MRQ Catalyst Pharmaceuticals Inc = 110,568
$34,844 / $110,568 = 0.32 or 31.5%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Catalyst Pharmaceuticals Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
7.4% Return on Assets means that Catalyst Pharmaceuticals Inc generated $0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Catalyst Pharmaceuticals Inc:

The MRQ is 7.4%. Using its assets, the company is efficient in making profit. +1
The TTM is 3.9%. Using its assets, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	7.4%	TTM	3.9%	+3.5%
TTM	3.9%	YOY	6.8%	-2.8%
TTM	3.9%	5Y	7.1%	-3.2%
5Y	7.1%	10Y	-1.6%	+8.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	7.4%	-13.3%	+20.7%
TTM	3.9%	-12.8%	+16.7%
YOY	6.8%	-11.7%	+18.5%
5Y	7.1%	-13.9%	+21.0%
10Y	-1.6%	-15.7%	+14.1%

Shows how efficient Catalyst Pharmaceuticals Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Catalyst Pharmaceuticals Inc is using its resources to generate profit. If the return on assets (7.4%) from Catalyst Pharmaceuticals Inc are higher than the Biotechnology mean (-13.3%) that means Catalyst Pharmaceuticals Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Catalyst Pharmaceuticals Inc is 7.4%. This means the company generated $0.07 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Catalyst Pharmaceuticals Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Catalyst Pharmaceuticals Inc = 34,844
Total assets MRQ (balance sheet) from Catalyst Pharmaceuticals Inc = 471,907
34,844 / 471,907 = 0.07 or 7.4%

ROA is an important ratio as it will tell you how effectively Catalyst Pharmaceuticals Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Catalyst Pharmaceuticals Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
9.0% Return on Equity means Catalyst Pharmaceuticals Inc generated $0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Catalyst Pharmaceuticals Inc:

The MRQ is 9.0%. Using its investors money, the company is less efficient in making profit.
The TTM is 4.8%. Using its investors money, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	9.0%	TTM	4.8%	+4.2%
TTM	4.8%	YOY	8.0%	-3.2%
TTM	4.8%	5Y	8.4%	-3.6%
5Y	8.4%	10Y	-1.5%	+9.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	9.0%	-16.9%	+25.9%
TTM	4.8%	-16.1%	+20.9%
YOY	8.0%	-15.1%	+23.1%
5Y	8.4%	-19.3%	+27.7%
10Y	-1.5%	-20.2%	+18.7%

Shows how efficient Catalyst Pharmaceuticals Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Catalyst Pharmaceuticals Inc is 9.0%. This means Catalyst Pharmaceuticals Inc generated $0.09 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if Catalyst Pharmaceuticals Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Catalyst Pharmaceuticals Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Catalyst Pharmaceuticals Inc = 34,844
Shareholders equity (balance sheet) MRQ Catalyst Pharmaceuticals Inc = 387,881
34,844 / 387,881 = 0.09 or 9.0%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Catalyst Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Catalyst Pharmaceuticals Inc is operating .

Measures how much profit Catalyst Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
An Operating Margin of 37.7% means the company generated $0.38 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Catalyst Pharmaceuticals Inc:

The MRQ is 37.7%. The company is operating very efficient. +2
The TTM is 22.5%. The company is operating efficient. +1

Trends

Current period		Compared to		+/-
MRQ	37.7%	TTM	22.5%	+15.2%
TTM	22.5%	YOY	46.9%	-24.4%
TTM	22.5%	5Y	33.3%	-10.7%
5Y	33.3%	10Y	-57.6%	+90.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	37.7%	-296.2%	+333.9%
TTM	22.5%	-232.5%	+255.0%
YOY	46.9%	-298.2%	+345.1%
5Y	33.3%	-492.1%	+525.4%
10Y	-57.6%	-632.4%	+574.8%

Measures how efficient Catalyst Pharmaceuticals Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Catalyst Pharmaceuticals Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Catalyst Pharmaceuticals Inc is 37.7%. This means that Catalyst Pharmaceuticals Inc earned $0.38 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -296.2%.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Catalyst Pharmaceuticals Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Catalyst Pharmaceuticals Inc = 41,692
Total revenue MRQ Catalyst Pharmaceuticals Inc = 110,568
$41,692 / $110,568 = 0.38 or 37.7%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Catalyst Pharmaceuticals Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.62 means that the operating costs are $0.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Catalyst Pharmaceuticals Inc:

The MRQ is 0.623. The company is efficient in keeping operating costs low. +1
The TTM is 0.775. The company is efficient in keeping operating costs low. +1

Trends

Current period		Compared to		+/-
MRQ	0.623	TTM	0.775	-0.152
TTM	0.775	YOY	0.528	+0.246
TTM	0.775	5Y	0.666	+0.109
5Y	0.666	10Y	1.100	-0.434

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.623	3.231	-2.608
TTM	0.775	3.310	-2.535
YOY	0.528	3.890	-3.362
5Y	0.666	5.739	-5.073
10Y	1.100	7.876	-6.776

Measures how efficient Catalyst Pharmaceuticals Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Catalyst Pharmaceuticals Inc is 62.3%. This means that Catalyst Pharmaceuticals Inc earned $0.62 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.23.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Catalyst Pharmaceuticals Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(24,868 +44,008) \ 110,568 = 0.62

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Catalyst Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Catalyst Pharmaceuticals Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 2.88 means the company has $2.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Catalyst Pharmaceuticals Inc:

The MRQ is 2.884. The company is able to pay all its short-term debts. +1
The TTM is 3.576. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	2.884	TTM	3.576	-0.692
TTM	3.576	YOY	8.046	-4.470
TTM	3.576	5Y	6.726	-3.151
5Y	6.726	10Y	12.316	-5.589

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.884	3.890	-1.006
TTM	3.576	4.173	-0.597
YOY	8.046	5.344	+2.702
5Y	6.726	6.126	+0.600
10Y	12.316	6.448	+5.868

Measures if Catalyst Pharmaceuticals Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Catalyst Pharmaceuticals Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Catalyst Pharmaceuticals Inc is 2.88. This means Catalyst Pharmaceuticals Inc has $2.88 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.89.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Catalyst Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
219,329 \ 76,063) = 2.88

The current ratio measures if Catalyst Pharmaceuticals Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Catalyst Pharmaceuticals Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Catalyst Pharmaceuticals Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Catalyst Pharmaceuticals Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Catalyst Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
A Quick Ratio of 2.51 means the company can pay off $2.51 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Catalyst Pharmaceuticals Inc:

The MRQ is 2.513. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 3.215. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	2.513	TTM	3.215	-0.702
TTM	3.215	YOY	7.986	-4.771
TTM	3.215	5Y	7.010	-3.795
5Y	7.010	10Y	17.870	-10.860

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.513	3.514	-1.001
TTM	3.215	3.998	-0.783
YOY	7.986	5.380	+2.606
5Y	7.010	6.105	+0.905
10Y	17.870	6.404	+11.466

Measures if Catalyst Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Catalyst Pharmaceuticals Inc can pay off its short term debts. This shows if Catalyst Pharmaceuticals Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Catalyst Pharmaceuticals Inc is 2.51. This means that Catalyst Pharmaceuticals Inc can pay off $2.51 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.51.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Catalyst Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Catalyst Pharmaceuticals Inc: (137,636 + 0 +53,514) / 76,063 = 2.51

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Catalyst Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Catalyst Pharmaceuticals Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Catalyst Pharmaceuticals Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.18 means that Catalyst Pharmaceuticals Inc assets are financed with 17.8% credit (debt) and the remaining percentage (100% - 17.8%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Catalyst Pharmaceuticals Inc:

The MRQ is 0.178. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.167. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.178	TTM	0.167	+0.011
TTM	0.167	YOY	0.149	+0.018
TTM	0.167	5Y	0.150	+0.018
5Y	0.150	10Y	0.121	+0.029

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.178	0.339	-0.161
TTM	0.167	0.336	-0.169
YOY	0.149	0.271	-0.122
5Y	0.150	0.366	-0.216
10Y	0.121	0.389	-0.268

Measures how much % of Catalyst Pharmaceuticals Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Catalyst Pharmaceuticals Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Catalyst Pharmaceuticals Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Catalyst Pharmaceuticals Inc is 0.18. This means means that Catalyst Pharmaceuticals Inc is financed with 17.8% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 389.0%.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Catalyst Pharmaceuticals Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Catalyst Pharmaceuticals Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
84,026 \ 471,907 = 17.8% or 0.18.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Catalyst Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 21.7% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Catalyst Pharmaceuticals Inc:

The MRQ is 0.217. The company is very able to pay all its debts with equity. +2
The TTM is 0.201. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.217	TTM	0.201	+0.015
TTM	0.201	YOY	0.179	+0.023
TTM	0.201	5Y	0.179	+0.023
5Y	0.179	10Y	0.142	+0.037

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.217	0.388	-0.171
TTM	0.201	0.402	-0.201
YOY	0.179	0.335	-0.156
5Y	0.179	0.426	-0.247
10Y	0.142	0.461	-0.319

Measures if Catalyst Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Catalyst Pharmaceuticals Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Catalyst Pharmaceuticals Inc is 0.22. This means that Catalyst Pharmaceuticals Inc can pay off $0.22 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Catalyst Pharmaceuticals Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
84,026 \ 387,881 = 0.22 or 21.7%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Catalyst Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Catalyst Pharmaceuticals Inc generates.

Above 15 is considered overpriced but always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
A PE ratio of 14.22 means the investor is paying $14.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Catalyst Pharmaceuticals Inc:

The EOD is 12.786. Based on the earnings, the company is underpriced. +1
The MRQ is 14.215. Based on the earnings, the company is underpriced. +1
The TTM is 7.507. Based on the earnings, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	12.786	MRQ	14.215	-1.429
MRQ	14.215	TTM	7.507	+6.708
TTM	7.507	YOY	16.535	-9.027
TTM	7.507	5Y	0.117	+7.390
5Y	0.117	10Y	-7.742	+7.860

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	12.786	-2.264	+15.050
MRQ	14.215	-2.629	+16.844
TTM	7.507	-2.680	+10.187
YOY	16.535	-4.145	+20.680
5Y	0.117	-6.257	+6.374
10Y	-7.742	-6.254	-1.488

Measures how much money you pay for each share for every $1 in earnings Catalyst Pharmaceuticals Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Catalyst Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Catalyst Pharmaceuticals Inc is 14.22. This means the investor is paying $14.22 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.63.
What is the trend?
The trend is important because it shows you how Catalyst Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Catalyst Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Catalyst Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Catalyst Pharmaceuticals Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 113,756 = EPS
PE ratio MRQ = 14.22

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Catalyst Pharmaceuticals Inc:

The EOD is 22.783. Based on how much money comes from the company's main activities, the company is underpriced. +1
The MRQ is 25.330. Based on how much money comes from the company's main activities, the company is underpriced. +1
The TTM is 17.217. Based on how much money comes from the company's main activities, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	22.783	MRQ	25.330	-2.547
MRQ	25.330	TTM	17.217	+8.113
TTM	17.217	YOY	14.972	+2.244
TTM	17.217	5Y	12.273	+4.944
5Y	12.273	10Y	-3.243	+15.517

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	22.783	-2.973	+25.756
MRQ	25.330	-3.333	+28.663
TTM	17.217	-3.553	+20.770
YOY	14.972	-5.605	+20.577
5Y	12.273	-8.376	+20.649
10Y	-3.243	-8.865	+5.622

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Catalyst Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 5.11 means the investor is paying $5.11 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Catalyst Pharmaceuticals Inc:

The EOD is 4.594. Based on the equity, the company is fair priced.
The MRQ is 5.108. Based on the equity, the company is overpriced. -1
The TTM is 4.785. Based on the equity, the company is fair priced.

Trends

Current period		Compared to		+/-
EOD	4.594	MRQ	5.108	-0.514
MRQ	5.108	TTM	4.785	+0.323
TTM	4.785	YOY	5.190	-0.406
TTM	4.785	5Y	4.975	-0.190
5Y	4.975	10Y	5.776	-0.801

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	4.594	1.896	+2.698
MRQ	5.108	2.115	+2.993
TTM	4.785	2.093	+2.692
YOY	5.190	2.884	+2.306
5Y	4.975	3.542	+1.433
10Y	5.776	3.916	+1.860

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Catalyst Pharmaceuticals Inc.

3.1. Institutions holding Catalyst Pharmaceuticals Inc

Institutions are holding 73.453% of the shares of Catalyst Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	13.4243	0.0068	15822299	439279	2.8556
2023-09-30	Deerfield Management Co	6.9504	2.1099	8192000	0	0
2023-12-31	Vanguard Group Inc	6.0413	0.0026	7120417	73930	1.0492
2023-12-31	State Street Corporation	5.7586	0.0056	6787332	-783363	-10.3473
2023-12-31	Dimensional Fund Advisors, Inc.	2.2075	0.0128	2601797	41923	1.6377
2023-12-31	Geode Capital Management, LLC	1.8668	0.0039	2200225	113858	5.4572
2023-12-31	Morgan Stanley - Brokerage Accounts	1.6642	0.0029	1961539	1048444	114.8231
2023-12-31	Goldman Sachs Group Inc	1.6263	0.0029	1916826	948507	97.954
2023-12-31	Royce & Associates, LP	1.4789	0.2706	1743074	131372	8.1511
2023-12-31	Renaissance Technologies Corp	1.3553	0.0416	1597427	308327	23.918
2023-12-31	Boston Partners Global Investors, Inc	1.308	0.0339	1541660	1396930	965.1973
2023-12-31	Northern Trust Corp	1.2037	0.0043	1418741	-18424	-1.282
2023-09-30	Jacobs Levy Equity Management, Inc.	1.1091	0.0905	1307225	-14056	-1.0638
2023-12-31	Opaleye Management Inc	1.0667	5.7001	1257200	52200	4.332
2023-12-31	LSV Asset Management	1.0442	0.0451	1230700	-10069	-0.8115
2023-12-31	T. Rowe Price Associates, Inc.	1.0152	0.0027	1196558	18390	1.5609
2023-12-31	HHG PLC	0.966	0.0114	1138594	730695	179.1363
2023-12-31	Charles Schwab Investment Management Inc	0.8114	0.0041	956333	35006	3.7995
2023-12-31	Amvescap Plc.	0.7803	0.0037	919647	-107954	-10.5054
2023-12-31	American Century Companies Inc	0.7785	0.0106	917578	18100	2.0123
Total		52.4567	8.366	61827172	+4423095	+7.2%

3.2. Funds holding Catalyst Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-03-28	iShares Core S&P Small-Cap ETF	6.4181	0.1501	7564637	10192	0.1349
2024-03-28	SPDR® S&P Biotech ETF	3.4409	0.8561	4055566	51160	1.2776
2024-02-29	Vanguard Total Stock Mkt Idx Inv	2.9454	0.0036	3471575	-13077	-0.3753
2024-03-28	iShares Russell 2000 ETF	2.3061	0.0662	2718045	1311	0.0483
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.3856	0.0257	1633154	-1477	-0.0904
2024-03-28	iShares S&P Small-Cap 600 Growth ETF	0.9276	0.2948	1093243	0	0
2024-01-31	Fidelity Small Cap Index	0.8626	0.0591	1016631	15311	1.5291
2024-03-28	SPDR® Portfolio S&P 600 Sm Cap ETF	0.8489	0.1517	1000505	1015	0.1016
2024-03-28	iShares Russell 2000 Growth ETF	0.8179	0.1319	964000	-1121	-0.1162
2023-12-31	T. Rowe Price Integrated US Sm Gr Eq	0.7424	0.1888	875000	23900	2.8081
2024-02-29	Vanguard Tax-Managed Small Cap Adm	0.7353	0.1563	866696	0	0
2024-02-29	DFA US Micro Cap I	0.6055	0.1596	713683	0	0
2024-02-29	Fidelity Extended Market Index	0.5405	0.0266	637050	20624	3.3457
2024-03-28	SPDR® S&P 600 Small Cap Growth ETF	0.5323	0.3001	627350	0	0
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.5116	0.0231	602971	10900	1.841
2024-02-29	DFA US Small Cap I	0.4915	0.0599	579289	0	0
2023-12-31	Royce Pennsylvania Mutual Invmt	0.4524	0.4801	533179	61790	13.1081
2023-12-31	Kennedy Small Cap Value	0.4478	1.3098	527746	-108620	-17.0688
2024-03-29	Schwab US Small-Cap ETF™	0.445	0.0489	524466	0	0
2024-02-29	Janus Henderson Glb Life Scn I2 USD	0.4367	0.2074	514757	4554	0.8926
Total		25.8941	4.6998	30519543	+76462	+0.3%

3.3. Insider Transactions

Insiders are holding 6.412% of the shares of Catalyst Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price
2024-03-27	Brian Elsbernd	SELL	25000	16.44
2023-12-12	David S Tierney	SELL	50000	13.32
2023-12-11	Alicia Grande	SELL	60000	13.76
2023-12-08	Alicia Grande	SELL	40000	14.28
2023-12-05	Steve Miller	SELL	40000	14.24
2023-05-15	Patrick J Mcenany	SELL	26151	13.23

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Catalyst Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.334	0.186	+80%	0.199	+68%	0.143	+133%	0.078	+329%
Book Value Per Share	-	-	3.291	3.066	+7%	2.189	+50%	1.725	+91%	1.075	+206%
Current Ratio	-	-	2.884	3.576	-19%	8.046	-64%	6.726	-57%	12.316	-77%
Debt To Asset Ratio	-	-	0.178	0.167	+6%	0.149	+20%	0.150	+19%	0.121	+48%
Debt To Equity Ratio	-	-	0.217	0.201	+8%	0.179	+21%	0.179	+21%	0.142	+53%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	0.296	0.151	+95%	0.176	+68%	0.128	+132%	0.041	+616%
Free Cash Flow Per Share	-	-	0.166	0.060	+179%	0.244	-32%	-8.097	+4980%	-4.067	+2551%
Free Cash Flow To Equity Per Share	-	-	0.160	0.037	+339%	0.248	-35%	-8.104	+5156%	-4.039	+2620%
Gross Profit Margin	-	-	0.170	0.697	-76%	0.628	-73%	0.665	-74%	0.833	-80%
Intrinsic Value_10Y_max	-	-	53.379	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-119.599	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	1.266	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-15.641	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	6.915	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-44.107	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	16.316	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-69.189	-	-	-	-	-	-	-	-
Market Cap	1782088560.000	-11%	1981277030.000	1724335690.000	+15%	1376934497.500	+44%	945614849.000	+110%	624143516.500	+217%
Net Profit Margin	-	-	0.315	0.185	+70%	0.383	-18%	0.348	-9%	-0.551	+275%
Operating Margin	-	-	0.377	0.225	+67%	0.469	-20%	0.333	+13%	-0.576	+253%
Operating Ratio	-	-	0.623	0.775	-20%	0.528	+18%	0.666	-6%	1.100	-43%
Pb Ratio	4.594	-11%	5.108	4.785	+7%	5.190	-2%	4.975	+3%	5.776	-12%
Pe Ratio	12.786	-11%	14.215	7.507	+89%	16.535	-14%	0.117	+12008%	-7.742	+154%
Price Per Share	15.120	-11%	16.810	14.630	+15%	11.683	+44%	8.023	+110%	5.296	+217%
Price To Free Cash Flow Ratio	22.783	-11%	25.330	17.217	+47%	14.972	+69%	12.273	+106%	-3.243	+113%
Price To Total Gains Ratio	45.308	-11%	50.372	23.924	+111%	59.239	-15%	120.167	-58%	21.908	+130%
Quick Ratio	-	-	2.513	3.215	-22%	7.986	-69%	7.010	-64%	17.870	-86%
Return On Assets	-	-	0.074	0.039	+88%	0.068	+9%	0.071	+4%	-0.016	+121%
Return On Equity	-	-	0.090	0.048	+88%	0.080	+13%	0.084	+7%	-0.015	+117%
Total Gains Per Share	-	-	0.334	0.186	+80%	0.199	+68%	0.143	+133%	0.078	+329%
Usd Book Value	-	-	387881000.000	361346000.000	+7%	257943750.000	+50%	203370917.050	+91%	126666286.325	+206%
Usd Book Value Change Per Share	-	-	0.334	0.186	+80%	0.199	+68%	0.143	+133%	0.078	+329%
Usd Book Value Per Share	-	-	3.291	3.066	+7%	2.189	+50%	1.725	+91%	1.075	+206%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	0.296	0.151	+95%	0.176	+68%	0.128	+132%	0.041	+616%
Usd Free Cash Flow	-	-	19555000.000	7020250.000	+179%	28749250.000	-32%	-954347771.500	+4980%	-479387859.525	+2551%
Usd Free Cash Flow Per Share	-	-	0.166	0.060	+179%	0.244	-32%	-8.097	+4980%	-4.067	+2551%
Usd Free Cash Flow To Equity Per Share	-	-	0.160	0.037	+339%	0.248	-35%	-8.104	+5156%	-4.039	+2620%
Usd Market Cap	1782088560.000	-11%	1981277030.000	1724335690.000	+15%	1376934497.500	+44%	945614849.000	+110%	624143516.500	+217%
Usd Price Per Share	15.120	-11%	16.810	14.630	+15%	11.683	+44%	8.023	+110%	5.296	+217%
Usd Profit	-	-	34844000.000	17852500.000	+95%	20769750.000	+68%	15041466.850	+132%	4864974.375	+616%
Usd Revenue	-	-	110568000.000	99551000.000	+11%	53550750.000	+106%	48730957.000	+127%	24377978.500	+354%
Usd Total Gains Per Share	-	-	0.334	0.186	+80%	0.199	+68%	0.143	+133%	0.078	+329%
	EOD	+4 -4	MRQ	TTM	+25 -9	YOY	+18 -16	5Y	+23 -11	10Y	+26 -8

4.2. Fundamental Score

Let's check the fundamental score of Catalyst Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	12.786
Price to Book Ratio (EOD)	Between	0-1	4.594
Net Profit Margin (MRQ)	Greater than	0	0.315
Operating Margin (MRQ)	Greater than	0	0.377
Quick Ratio (MRQ)	Greater than	1	2.513
Current Ratio (MRQ)	Greater than	1	2.884
Debt to Asset Ratio (MRQ)	Less than	1	0.178
Debt to Equity Ratio (MRQ)	Less than	1	0.217
Return on Equity (MRQ)	Greater than	0.15	0.090
Return on Assets (MRQ)	Greater than	0.05	0.074
Total			8/10 (80.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Catalyst Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	45.750
Ma 20	Greater than	Ma 50	15.478
Ma 50	Greater than	Ma 100	15.438
Ma 100	Greater than	Ma 200	15.119
Open	Greater than	Close	14.800
Total			3/5 (60.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	471,907
Total Liabilities	84,026
Total Stockholder Equity	387,881

	As reported
Total Liabilities	84,026
Total Stockholder Equity	+ 387,881
Total Assets	= 471,907

Assets

Total Assets	471,907
Total Current Assets	219,329
Long-term Assets	252,578

Total Current Assets

Total Current Assets (as reported)	219,329
Cash And Cash Equivalents	137,636
Net Receivables	53,514
Inventory	15,644
Other Current Assets	12,535
Total Current Assets (calculated)	219,329
+/-	0

Long-term Assets

Long-term Assets (as reported)	252,578
Property Plant Equipment	3,703
Long Term Investments	16,489
Intangible Assets	194,049
Other Assets	0
Long-term Assets (calculated)	214,241
+/-	38,337

Liabilities & Shareholders' Equity

Total Current Liabilities	76,063
Long-term Liabilities	7,963
Total Stockholder Equity	387,881

Total Current Liabilities

Total Current Liabilities (as reported)	76,063
Short-term Debt	369
Accounts payable	14,795
Other Current Liabilities	60,170
Total Current Liabilities (calculated)	75,334
+/-	729

Long-term Liabilities

Long-term Liabilities (as reported)	7,963
Capital Lease Obligations	3,557
Long-term Liabilities Other	485
Long-term Liabilities (calculated)	4,042
+/-	3,921

Total Stockholder Equity

Total Stockholder Equity (as reported)	387,881
Common Stock	107
Retained Earnings	121,272
Accumulated Other Comprehensive Income	14
Other Stockholders Equity	266,488
Total Stockholder Equity (calculated)	387,881
+/-	0

Other

Capital Stock	107
Cash and Short Term Investments	137,636
Common Stock Shares Outstanding	113,756
Current Deferred Revenue	729
Liabilities and Stockholders Equity	471,907
Net Debt	-134,079
Net Invested Capital	387,881
Net Working Capital	143,266
Property Plant and Equipment Gross	4,426
Short Long Term Debt Total	3,557

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

> Total Assets

0
0
0
185
0
0
0
789
0
365
3,512
20,619
20,619
18,247
17,593
16,680
15,489
13,535
15,348
12,033
9,248
6,481
5,078
7,966
7,037
5,911
6,415
5,831
7,156
5,610
4,298
6,249
4,989
7,704
12,105
16,789
16,789
12,545
28,695
25,370
22,230
45,929
45,845
43,908
76,050
68,337
64,563
60,102
53,666
48,941
45,313
41,707
37,697
35,980
34,631
85,387
79,128
74,288
67,710
60,450
61,077
78,234
96,691
112,376
117,880
131,412
174,860
192,354
197,216
209,130
223,248
237,788
246,972
267,309
333,114
375,630
407,227
443,896
413,211
471,907

471,907

413,211

443,896

407,227

375,630

333,114

267,309

246,972

237,788

223,248

209,130

197,216

192,354

174,860

131,412

117,880

112,376

96,691

78,234

61,077

60,450

67,710

74,288

79,128

85,387

34,631

35,980

37,697

41,707

45,313

48,941

53,666

60,102

64,563

68,337

76,050

43,908

45,845

45,929

22,230

25,370

28,695

12,545

16,789

12,105

7,704

4,989

6,249

4,298

5,610

7,156

5,831

6,415

5,911

7,037

7,966

5,078

6,481

9,248

12,033

15,348

13,535

15,489

16,680

17,593

18,247

20,619

3,512

365

789

185

> Total Current Assets

0
0
0
184
0
0
0
772
0
327
3,007
20,588
20,588
18,177
17,448
16,532
15,343
13,397
15,218
11,915
9,146
6,390
4,994
7,887
6,964
5,845
6,356
5,775
7,101
5,574
4,269
6,228
4,966
7,682
12,085
16,727
16,727
12,484
28,640
25,320
22,168
45,855
45,764
43,828
75,970
68,265
64,356
59,901
53,479
48,673
45,055
41,454
37,457
35,753
34,417
85,187
78,936
69,086
62,481
55,187
54,862
72,056
90,579
111,364
116,944
131,164
143,342
159,244
161,533
176,305
192,795
210,106
221,191
242,558
276,310
320,797
198,911
240,968
192,017
219,329

219,329

192,017

240,968

198,911

320,797

276,310

242,558

221,191

210,106

192,795

176,305

161,533

159,244

143,342

131,164

116,944

111,364

90,579

72,056

54,862

55,187

62,481

69,086

78,936

85,187

34,417

35,753

37,457

41,454

45,055

48,673

53,479

59,901

64,356

68,265

75,970

43,828

45,764

45,855

22,168

25,320

28,640

12,484

16,727

12,085

7,682

4,966

6,228

4,269

5,574

7,101

5,775

6,356

5,845

6,964

7,887

4,994

6,390

9,146

11,915

15,218

13,397

15,343

16,532

17,448

18,177

20,588

3,007

327

772

184

Cash And Cash Equivalents

0
0
0
184
0
0
0
771
0
324
3,003
20,435
20,435
17,600
16,886
15,944
14,717
13,084
15,027
11,767
8,930
6,266
4,912
7,779
6,758
5,608
6,247
5,475
6,873
3,406
2,151
6,029
4,723
7,515
11,974
1,410
1,410
879
12,963
2,216
1,072
14,802
11,264
9,097
41,323
37,221
32,750
28,235
22,228
18,717
17,638
13,893
9,981
8,584
7,329
57,497
19,601
9,888
10,616
16,559
19,082
23,418
44,983
89,512
101,751
115,052
117,106
130,237
127,328
135,295
154,836
171,445
178,372
210,912
256,065
298,395
148,247
178,787
120,971
137,636

137,636

120,971

178,787

148,247

298,395

256,065

210,912

178,372

171,445

154,836

135,295

127,328

130,237

117,106

115,052

101,751

89,512

44,983

23,418

19,082

16,559

10,616

9,888

19,601

57,497

7,329

8,584

9,981

13,893

17,638

18,717

22,228

28,235

32,750

37,221

41,323

9,097

11,264

14,802

1,072

2,216

12,963

879

1,410

11,974

7,515

4,723

6,029

2,151

3,406

6,873

5,475

6,247

5,608

6,758

7,779

4,912

6,266

8,930

11,767

15,027

13,084

14,717

15,944

16,886

17,600

20,435

3,003

324

771

184

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,002
2,004
0
0
0
0
14,007
14,007
10,491
14,688
21,495
20,212
30,211
30,183
30,178
30,214
30,182
30,212
30,161
30,227
29,305
27,106
26,513
26,546
26,548
26,578
26,517
58,343
58,521
51,048
36,922
26,551
36,503
31,562
5,007
5,007
0
10,003
10,041
15,971
19,980
19,956
19,821
19,424
9,876
0
0
0
0
0
0

9,876

19,424

19,821

19,956

19,980

15,971

10,041

10,003

5,007

31,562

36,503

26,551

36,922

51,048

58,521

58,343

26,517

26,578

26,548

26,546

26,513

27,106

29,305

30,227

30,161

30,212

30,182

30,214

30,178

30,183

30,211

20,212

21,495

14,688

10,491

14,007

2,004

2,002

Net Receivables

0
0
0
0
0
0
0
0
0
0
0
86
86
79
66
64
41
24
17
12
3
0
0
0
0
0
0
134
134
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,500
3,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,251
10,376
10,095
10,537
6,919
6,762
6,179
5,987
6,005
9,209
6,822
6,619
10,784
9,804
9,661
10,439
33,402
42,796
48,049
53,514

53,514

48,049

42,796

33,402

10,439

9,661

9,804

10,784

6,619

6,822

9,209

6,005

5,987

6,179

6,762

6,919

10,537

10,095

10,376

7,251

3,500

134

Other Current Assets

0
0
0
0
0
0
0
0
0
3
3
67
67
498
496
524
585
288
173
136
214
125
82
108
207
237
109
166
228
2,002
2,004
199
243
167
112
7,812
15
10
24
23
59
32
45
34
109
861
53
1,505
36
35
36
1,048
57
34
50
1,174
52
677
191
1,650
1,881
382
431
4,351
327
292
590
8,328
276
321
228
4,351
433
394
466
5,158
6,934
361
352
12,535

12,535

352

361

6,934

5,158

466

394

433

4,351

228

321

276

8,328

590

292

327

4,351

431

382

1,881

1,650

191

677

1,174

1,048

1,505

861

109

7,812

112

167

243

199

2,004

2,002

228

166

109

237

207

108

125

214

136

173

288

585

524

496

498

> Long-term Assets

0
0
0
1
0
0
0
18
0
38
505
0
32
70
146
148
146
138
130
118
101
91
84
79
72
66
60
56
55
36
29
21
23
22
20
63
63
61
55
50
62
74
80
80
80
72
207
200
187
267
258
253
240
227
214
200
192
5,201
5,229
5,263
6,215
6,178
6,111
1,013
936
248
31,518
33,110
35,683
32,825
30,453
27,682
25,781
24,751
56,804
54,833
208,316
202,928
221,194
252,578

252,578

221,194

202,928

208,316

54,833

56,804

24,751

25,781

27,682

30,453

32,825

35,683

33,110

31,518

248

936

1,013

6,111

6,178

6,215

5,263

5,229

5,201

192

200

214

227

240

253

258

267

187

200

207

101

118

130

138

146

148

146

505

Property Plant Equipment

0
0
0
1
0
0
0
4
0
14
20
20
20
50
126
128
121
113
105
96
88
81
73
68
62
55
49
46
45
26
18
12
14
14
11
54
54
52
46
41
53
65
71
71
71
63
198
192
178
259
249
244
231
218
205
191
183
187
201
245
1,214
1,161
1,093
1,004
927
239
161
130
4,253
4,115
4,044
3,976
3,882
3,812
3,715
3,617
3,991
3,844
3,761
3,703

3,703

3,761

3,844

3,991

3,617

3,715

3,812

3,882

3,976

4,044

4,115

4,253

130

161

239

927

1,004

1,093

1,161

1,214

245

201

187

183

191

205

218

231

244

249

259

178

192

198

105

113

121

128

126

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,005
5,019
5,008
4,992
5,008
5,009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,897
16,489

16,489

12,897

5,009

5,008

4,992

5,008

5,019

5,005

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,051
32,471
184,083
175,595
167,108
194,049

194,049

167,108

175,595

184,083

32,471

33,051

Other Assets

0
0
0
0
0
0
0
13
0
24
485
11
20
20
20
20
25
25
25
22
13
11
11
11
11
11
11
11
10
11
11
9
9
8
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
31,356
32,980
31,430
28,710
26,409
23,706
21,899
20,939
20,038
18,745
0
23,489
0
0

23,489

18,745

20,038

20,939

21,899

23,706

26,409

28,710

31,430

32,980

31,356

485

> Total Liabilities

0
0
0
68
0
0
0
343
0
434
687
773
773
418
405
357
489
789
1,266
1,473
1,576
507
315
349
381
499
415
314
873
656
423
2,489
2,272
1,293
2,710
2,167
2,167
2,701
6,576
3,978
4,591
4,741
9,222
8,666
9,427
5,545
3,913
4,625
3,129
2,616
2,410
2,398
2,601
2,011
2,902
4,424
2,882
3,225
3,633
9,666
9,901
14,953
18,708
24,746
18,204
20,210
18,232
22,756
18,565
20,186
24,587
30,957
26,751
26,217
63,073
75,209
73,566
68,602
64,663
84,026

84,026

64,663

68,602

73,566

75,209

63,073

26,217

26,751

30,957

24,587

20,186

18,565

22,756

18,232

20,210

18,204

24,746

18,708

14,953

9,901

9,666

3,633

3,225

2,882

4,424

2,902

2,011

2,601

2,398

2,410

2,616

3,129

4,625

3,913

5,545

9,427

8,666

9,222

4,741

4,591

3,978

6,576

2,701

2,167

2,710

1,293

2,272

2,489

423

656

873

314

415

499

381

349

315

507

1,576

1,473

1,266

789

489

357

405

418

773

687

434

343

> Total Current Liabilities

0
0
0
68
0
0
0
343
0
434
687
773
773
418
405
303
438
740
1,221
1,430
1,537
471
266
294
335
451
396
299
862
656
423
834
879
677
753
1,647
1,647
1,638
3,012
2,140
2,437
2,364
5,939
5,855
5,849
2,553
2,386
3,441
2,664
2,305
1,996
2,095
1,906
1,840
2,738
4,266
2,731
3,082
3,468
9,511
9,026
14,152
17,982
24,099
17,636
20,210
18,232
22,756
14,436
16,135
20,614
27,063
22,938
22,488
44,681
57,588
56,709
52,503
57,806
76,063

76,063

57,806

52,503

56,709

57,588

44,681

22,488

22,938

27,063

20,614

16,135

14,436

22,756

18,232

20,210

17,636

24,099

17,982

14,152

9,026

9,511

3,468

3,082

2,731

4,266

2,738

1,840

1,906

2,095

1,996

2,305

2,664

3,441

2,386

2,553

5,849

5,855

5,939

2,364

2,437

2,140

3,012

1,638

1,647

753

677

879

834

423

656

862

299

396

451

335

294

266

471

1,537

1,430

1,221

740

438

303

405

418

773

687

434

343

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
235
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
283
288
294
301
307
198
115
29
122
200
278
308
316
322
330
337
345
353
361
369

369

361

353

345

337

330

322

316

308

278

200

122

115

198

307

301

294

288

283

235

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
283
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

283

Accounts payable

0
0
0
31
0
0
0
68
0
25
418
448
448
146
229
220
317
181
636
333
738
276
163
250
88
252
241
106
425
478
174
264
350
223
356
1,647
1,366
448
1,473
851
932
1,238
525
1,814
1,051
1,316
817
1,794
1,251
707
1,055
933
918
692
1,082
1,946
805
923
1,341
2,337
2,940
3,329
4,147
4,117
1,348
5,805
2,005
4,256
2,561
2,924
2,752
2,768
5,139
2,315
2,529
3,975
3,391
4,421
4,598
14,795

14,795

4,598

4,421

3,391

3,975

2,529

2,315

5,139

2,768

2,752

2,924

2,561

4,256

2,005

5,805

1,348

4,117

4,147

3,329

2,940

2,337

1,341

923

805

1,946

1,082

692

918

933

1,055

707

1,251

1,794

817

1,316

1,051

1,814

525

1,238

932

851

1,473

448

1,366

1,647

356

223

350

264

174

478

425

106

241

252

250

163

276

738

333

636

181

317

220

229

146

448

418

Other Current Liabilities

0
0
0
37
0
0
0
275
0
409
269
324
325
272
176
83
122
559
585
1,097
799
195
103
45
246
199
155
193
437
178
9
570
529
454
397
282
281
1,189
1,538
1,289
1,505
1,126
5,414
4,041
4,798
1,237
1,569
1,646
1,412
1,598
940
1,161
988
1,148
1,656
2,321
1,926
2,159
2,127
7,174
166
153
531
172
140
31
70
107
111
112
110
243
17,483
19,851
41,822
53,276
52,973
455
374
60,170

60,170

374

455

52,973

53,276

41,822

19,851

17,483

243

110

112

111

107

140

172

531

153

166

7,174

2,127

2,159

1,926

2,321

1,656

1,148

988

1,161

940

1,598

1,412

1,646

1,569

1,237

4,798

4,041

5,414

1,126

1,505

1,289

1,538

1,189

281

282

397

454

529

570

178

437

193

155

199

246

103

195

799

1,097

585

559

122

176

272

325

324

269

409

275

> Long-term Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54
51
49
46
43
40
36
50
54
47
47
19
15
11
0
0
1,655
1,393
616
1,957
520
520
1,063
3,564
1,839
2,155
2,377
3,283
2,811
3,578
2,991
1,527
1,185
465
310
414
303
695
171
165
157
150
143
165
155
875
801
726
648
568
0
0
0
4,129
4,051
3,973
3,894
3,813
3,729
18,392
17,621
16,857
16,099
6,857
7,963

7,963

6,857

16,099

16,857

17,621

18,392

3,729

3,813

3,894

3,973

4,051

4,129

568

648

726

801

875

155

165

143

150

157

165

171

695

303

414

310

465

1,185

1,527

2,991

3,578

2,811

3,283

2,377

2,155

1,839

3,564

1,063

520

1,957

616

1,393

1,655

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54
51
49
45
43
40
36
49
54
47
48
19
14
11
0
0
1,654
1,393
616
1,957
520
565
1,063
3,564
1,839
2,155
2,377
3,283
2,811
3,578
2,992
1,527
1,185
465
311
414
303
695
171
164
157
150
143
165
155
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,749
14,064
0
12,723
0
0

12,723

14,064

14,749

155

165

143

150

157

164

171

695

303

414

311

465

1,185

1,527

2,992

3,578

2,811

3,283

2,377

2,155

1,839

3,564

1,063

565

520

1,957

616

1,393

1,654

> Total Stockholder Equity

0
0
0
118
0
0
0
446
0
-69
2,825
19,847
19,847
17,828
17,188
16,323
15,000
12,746
14,082
10,560
7,671
5,974
4,763
7,618
6,655
5,412
6,001
5,518
6,283
4,954
3,875
3,761
2,717
6,411
9,395
14,622
14,622
9,844
22,119
21,391
17,638
41,188
36,623
35,242
66,622
62,792
60,650
55,476
50,537
46,325
42,903
39,309
35,096
33,969
31,729
80,964
76,246
71,062
64,077
50,784
51,176
63,282
77,983
87,630
99,676
111,201
156,628
169,598
178,651
188,944
198,661
206,831
220,221
241,092
270,041
300,421
333,661
375,294
348,548
387,881

387,881

348,548

375,294

333,661

300,421

270,041

241,092

220,221

206,831

198,661

188,944

178,651

169,598

156,628

111,201

99,676

87,630

77,983

63,282

51,176

50,784

64,077

71,062

76,246

80,964

31,729

33,969

35,096

39,309

42,903

46,325

50,537

55,476

60,650

62,792

66,622

35,242

36,623

41,188

17,638

21,391

22,119

9,844

14,622

9,395

6,411

2,717

3,761

3,875

4,954

6,283

5,518

6,001

5,412

6,655

7,618

4,763

5,974

7,671

10,560

14,082

12,746

15,000

16,323

17,188

17,828

19,847

2,825

-69

446

118

Common Stock

0
0
0
29
0
0
0
69
0
69
7
13
13
13
13
13
13
13
14
14
14
14
14
18
18
18
19
19
22
22
22
25
25
31
35
41
41
41
54
54
54
67
67
69
82
82
83
83
83
83
83
83
83
85
85
103
103
103
103
103
103
103
103
103
103
103
104
104
104
103
103
103
103
103
104
105
106
107
107
107

107

106

105

104

103

104

103

Retained Earnings Total Equity

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-34,623
-35,751
-38,103
-39,192
-39,481
-42,102
-42,179
-43,923
-47,067
-52,979
-54,334
-58,145
-61,343
-66,353
-69,843
-75,253
-79,811
-84,260
-90,076
-95,462
-100,031
-103,985
-108,148
-113,115
-116,995
-121,173
-126,560
-132,260
-138,225
-146,064
-160,564
-161,208
-150,249
-136,618
-128,689
-118,263
-108,483
-65,143
0
-46,335
-37,821
-32,544
-26,310
-15,620
1,643
24,391
49,862
79,430
0
0
0

79,430

49,862

24,391

1,643

-15,620

-26,310

-32,544

-37,821

-46,335

-65,143

-108,483

-118,263

-128,689

-136,618

-150,249

-161,208

-160,564

-146,064

-138,225

-132,260

-126,560

-121,173

-116,995

-113,115

-108,148

-103,985

-100,031

-95,462

-90,076

-84,260

-79,811

-75,253

-69,843

-66,353

-61,343

-58,145

-54,334

-52,979

-47,067

-43,923

-42,179

-42,102

-39,481

-39,192

-38,103

-35,751

-34,623

Accumulated Other Comprehensive Income

0
0
0
0
0
0
0
-2
0
-4
-6
-7
-7
-11
-15
-22
-31
-39
-47
-55
-63
-71
-78
-85
-92
-98
-105
-111
-112
-133
-141
-59
-62
-65
-67
-70
-70
-81
-87
-92
-92
-98
-105
-113
-121
-130
-100
-70
-83
-92
-102
-113
-126
-139
-152
-159
-22
-36
-46
-20
-7
22
19
10
84
-1
-6
31
-45
-37
-63
-148
-453
-130
32
24
11
19
15
14

-130

-453

-148

-63

-37

-45

-6

-1

-7

-20

-46

-36

-22

-159

-152

-139

-126

-113

-102

-92

-83

-70

-100

-130

-121

-113

-105

-98

-92

-87

-81

-70

-67

-65

-62

-59

-141

-133

-112

-111

-105

-98

-92

-85

-78

-71

-63

-55

-47

-39

-31

-22

-15

-11

-7

-6

-4

-2

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,555
39,604
41,839
41,884
45,861
51,463
56,760
56,801
56,870
75,044
75,671
75,729
102,464
102,908
105,016
141,793
142,521
144,827
145,469
145,916
146,273
146,805
147,374
148,128
150,880
152,817
207,422
208,426
209,222
210,084
211,265
212,288
213,405
214,478
216,206
217,751
219,582
221,673
0
224,927
226,699
231,165
233,186
236,191
239,476
245,514
250,430
254,114
0
0
0

254,114

250,430

245,514

239,476

236,191

233,186

231,165

226,699

224,927

221,673

219,582

217,751

216,206

214,478

213,405

212,288

211,265

210,084

209,222

208,426

207,422

152,817

150,880

148,128

147,374

146,805

146,273

145,916

145,469

144,827

142,521

141,793

105,016

102,908

102,464

75,729

75,671

75,044

56,870

56,801

56,760

51,463

45,861

41,884

41,839

39,604

39,555

Treasury Stock

Other Stockholders Equity

0
0
0
1,312
0
0
0
3,408
0
3,562
7,842
0
25,600
26,047
26,144
26,231
26,501
26,632
30,830
31,065
31,215
31,287
31,370
35,390
35,480
35,572
37,069
37,321
39,602
39,689
39,745
41,898
41,946
45,926
51,530
0
56,830
56,951
75,131
75,763
75,821
102,562
103,013
105,129
141,915
142,652
144,927
145,539
145,999
146,365
146,907
147,488
148,255
151,019
152,969
207,581
208,426
209,222
210,084
211,265
212,288
213,405
214,478
216,206
217,751
219,582
221,673
223,168
224,927
226,699
231,165
233,186
236,191
239,476
245,514
250,430
254,114
257,976
261,998
266,488

266,488

261,998

257,976

254,114

250,430

245,514

239,476

236,191

233,186

231,165

226,699

224,927

223,168

221,673

219,582

217,751

216,206

214,478

213,405

212,288

211,265

210,084

209,222

208,426

207,581

152,969

151,019

148,255

147,488

146,907

146,365

145,999

145,539

144,927

142,652

141,915

105,129

103,013

102,562

75,821

75,763

75,131

56,951

56,830

51,530

45,926

41,946

41,898

39,745

39,689

39,602

37,321

37,069

35,572

35,480

35,390

31,370

31,287

31,215

31,065

30,830

26,632

26,501

26,231

26,144

26,047

25,600

7,842

3,562

3,408

1,312

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31
Accounts Payable	14,795	3,975	2,768	4,256	4,117	2,337	1,946	933	1,794	1,814	851	1,366	264	106	250	333	220	448	68	31	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Other Comprehensive Income	14	24	-148	31	10	-20	-159	-113	-70	-113	-92	-70	-59	-111	-85	-55	-22	-7	-2	0	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Lease Obligations	3,557	3,894	3,894	29	948	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Stock	107	105	103	104	103	103	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Surpluse	0	250,430	233,186	0	216,206	211,265	207,422	147,374	145,469	105,016	75,671	56,760	41,839	0	0	0	0	0	0	0	-	-
Cash	137,636	298,395	171,445	130,237	89,512	16,559	57,497	13,893	28,235	9,097	2,216	1,410	6,029	5,475	7,779	11,767	15,944	20,435	771	184	-	107
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Cash And Short Term Investments	137,636	298,395	191,266	140,278	94,519	53,482	84,013	40,406	58,396	39,275	23,711	15,417	6,029	5,475	7,779	11,767	15,944	20,435	771	184	-	107
Common Stock	107	105	103	104	103	103	103	83	83	69	54	41	25	19	18	14	13	13	69	29	-	-
Common Stock Shares Outstanding	113,753	111,376	107,796	106,242	106,021	102,634	85,802	82,875	80,858	64,143	45,452	30,033	21,728	18,580	15,067	13,013	12,525	7,688	6,205	2,918	2,918	2,359
Common Stock Total Equity	0	105	103	104	103	103	103	83	83	69	54	41	25	19	18	14	13	13	69	29	-	-
Current Deferred Revenue	729	0	23,744	18,364	19,508	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Intangible Assets	194,049	32,471	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Inventory	15,644	6,805	7,870	4,651	1,957	56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Liabilities And Stockholders Equity	471,907	375,630	237,788	192,354	112,376	60,450	85,387	41,707	60,102	43,908	25,370	16,789	6,249	5,831	7,966	12,033	16,680	20,619	789	185	-	112
Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Long Term Investments	16,489	0	0	0	0	5,008	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Debt	-134,079	-294,501	-167,551	-130,208	-88,864	-16,559	-57,497	-13,893	-28,235	-9,097	-2,216	-1,410	-6,029	-5,475	-7,779	-11,767	-15,944	-20,435	-771	-184	-	-107
Net Invested Capital	387,881	300,421	206,831	169,598	87,630	50,784	80,964	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Receivables	53,514	10,439	6,619	5,987	10,537	0	0	0	0	3,500	0	0	0	134	0	12	64	86	0	0	-	-
Net Tangible Assets	0	267,950	206,831	169,598	87,630	50,784	80,964	39,309	55,476	35,242	21,391	14,622	3,761	0	0	0	0	0	0	0	-	-
Net Working Capital	143,266	263,209	183,043	136,488	87,265	45,676	80,921	39,359	56,461	37,973	23,180	15,080	5,394	5,476	7,593	10,485	16,228	19,815	429	116	-	-
Non Current Assets Total	252,578	54,833	27,682	33,110	1,013	5,263	200	253	200	80	50	63	21	56	79	118	148	32	18	1	-	-
Non Current Liabilities Other	485	17,621	3,894	0	648	155	157	303	1,185	2,811	1,839	520	1,655	0	0	0	0	0	0	0	-	-
Non Current Liabilities Total	7,963	17,621	3,894	4,285	648	155	157	303	1,185	2,811	1,839	520	1,655	15	54	43	54	0	0	0	-	-
Non Currrent Assets Other	0	9	9	9	9	9	9	9	9	9	9	9	9	11	11	21	20	12	14	0	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Assets	0	18,745	23,706	32,980	9	9	9	9	9	9	9	9	9	11	11	22	20	11	13	0	-	112
Other Current Assets	12,535	5,158	4,351	8,328	4,351	1,650	1,174	1,048	1,505	34	23	1,309	199	166	108	136	524	67	0	0	-	-
Other Current Liab	60,170	53,276	243	107	172	7,174	2,321	1,161	1,646	4,041	1,289	281	570	193	45	1,097	83	325	275	37	-	-
Other Liab	0	14,064	0	0	0	155	157	303	1,185	2,811	1,839	520	1,654	14	54	43	54	0	0	0	-	-
Other Stockholder Equity	266,488	250,430	233,186	223,168	216,206	211,265	207,581	147,488	145,539	105,129	75,763	56,830	41,898	37,321	35,390	31,065	26,231	25,600	3,408	1,312	-	45
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	-	-
Property Plant And Equipment Gross	4,426	3,617	3,976	130	1,004	245	191	244	192	71	41	54	12	46	68	96	128	20	4	1	-	-
Property Plant And Equipment Net	3,703	3,617	3,976	130	1,004	245	191	244	192	71	41	54	12	46	68	96	128	20	4	1	-	-
Property Plant Equipment	0	847	3,976	130	210	245	191	244	192	71	41	54	12	45	68	96	128	20	4	1	-	-
Retained Earnings	121,272	49,862	-26,310	-53,706	-128,689	-160,564	-126,560	-108,148	-90,076	-69,843	-54,334	-42,179	-38,103	-31,712	-27,705	-20,463	-9,899	-5,759	-3,030	-1,224	-	-
Retained Earnings Total Equity	0	49,862	-26,310	0	-128,689	-160,564	-126,560	-108,148	-90,076	-69,843	-54,334	-42,179	-38,103	0	0	0	0	0	0	0	-	-
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt Total	3,557	3,894	3,894	29	648	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Short Term Debt	369	337	308	29	301	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Short Term Investments	0	0	19,821	10,041	5,007	36,922	26,517	26,513	30,161	30,178	21,495	14,007	0	0	0	0	0	0	0	0	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Assets	471,907	375,630	237,788	192,354	112,376	60,450	85,387	41,707	60,102	43,908	25,370	16,789	6,249	5,831	7,966	12,033	16,680	20,619	789	185	-	112
Total Current Assets	219,329	320,797	210,106	159,244	111,364	55,187	85,187	41,454	59,901	43,828	25,320	16,727	6,228	5,775	7,887	11,915	16,532	20,588	772	184	-	107
Total Current Liabilities	76,063	57,588	27,063	22,756	24,099	9,511	4,266	2,095	3,441	5,855	2,140	1,647	834	299	294	1,430	303	773	343	68	-	-
Total Liab	84,026	75,209	30,957	22,756	24,746	9,666	4,424	2,398	4,625	8,666	3,978	2,167	2,489	314	349	1,473	357	773	343	68	-	67
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Stockholder Equity	387,881	300,421	206,831	169,598	87,630	50,784	80,964	39,309	55,476	35,242	21,391	14,622	3,761	5,518	7,618	10,560	16,323	19,847	446	118	-	45
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31
Accounts Payable	14,795	4,598	4,421	3,391	3,975	2,529	2,315	5,139	2,768	2,752	2,924	2,561	4,256	2,005	5,805	1,348	4,117	4,147	3,329	2,940	2,337	1,341	923	805	1,946	1,082	692	918	933	1,055	707	1,251	1,794	817	1,316	1,051	1,814	525	1,238	932	851	1,473	448	1,366	1,647	356	223	350	264	174	478	425	106	241	252	88	250	163	276	738	333	636	181	317	220	229	146	448	448	418	25	-	68	-	-	-	31	-	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Accumulated Other Comprehensive Income	14	15	19	11	24	32	-130	-453	-148	-63	-37	-45	31	-6	-1	84	10	19	22	-7	-20	-46	-36	-22	-159	-152	-139	-126	-113	-102	-92	-83	-70	-100	-130	-121	-113	-105	-98	-92	-92	-87	-81	-70	-70	-67	-65	-62	-59	-141	-133	-112	-111	-105	-98	-92	-85	-78	-71	-63	-55	-47	-39	-31	-22	-15	-11	-7	-7	-6	-4	-	-2	-	-	-	0	-	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Capital Lease Obligations	3,557	3,643	3,729	3,468	3,894	3,973	4,051	4,129	3,894	4,251	4,251	4,251	29	115	198	875	948	1,020	1,090	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Capital Stock	107	107	107	106	105	104	103	103	103	103	103	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Capital Surpluse	0	0	0	254,114	250,430	245,514	239,476	236,191	233,186	231,165	226,699	224,927	0	221,673	219,582	217,751	216,206	214,478	213,405	212,288	211,265	210,084	209,222	208,426	207,422	152,817	150,880	148,128	147,374	146,805	146,273	145,916	145,469	144,827	142,521	141,793	105,016	102,908	102,464	75,729	75,671	75,044	56,870	56,801	56,760	51,463	45,861	41,884	41,839	39,604	39,555	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Cash	137,636	120,971	178,787	148,247	298,395	256,065	210,912	178,372	171,445	154,836	135,295	127,328	130,237	117,106	115,052	101,751	89,512	44,983	23,418	19,082	16,559	10,616	9,888	19,601	57,497	7,329	8,584	9,981	13,893	17,638	18,717	22,228	28,235	32,750	37,221	41,323	9,097	11,264	14,802	1,072	2,216	12,963	879	1,410	1,410	11,974	7,515	4,723	6,029	2,151	3,406	6,873	5,475	6,247	5,608	6,758	7,779	4,912	6,266	8,930	11,767	15,027	13,084	14,717	15,944	16,886	17,600	20,435	20,435	3,003	324	-	771	-	-	-	184	-	-	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Cash And Short Term Investments	137,636	120,971	178,787	148,247	298,395	256,065	220,788	197,796	191,266	174,792	155,275	143,299	140,278	127,109	115,052	101,751	94,519	76,545	59,921	45,633	53,482	61,664	68,409	77,943	84,013	33,906	35,131	36,527	40,406	44,744	48,022	52,455	58,396	62,962	67,403	71,537	39,275	41,447	45,013	21,285	23,711	27,651	11,370	15,417	8,914	11,974	7,515	4,723	6,029	2,151	3,406	6,873	5,475	6,247	5,608	6,758	7,779	4,912	6,266	8,930	11,767	15,027	13,084	14,717	15,944	16,886	17,600	20,435	0	3,003	324	-	771	-	-	-	184	-	-	-
Common Stock	107	107	107	106	105	104	103	103	103	103	103	104	104	104	103	103	103	103	103	103	103	103	103	103	103	85	85	83	83	83	83	83	83	83	82	82	69	67	67	54	54	54	41	41	41	35	31	25	25	22	22	22	19	19	18	18	18	14	14	14	14	14	13	13	13	13	13	13	13	7	69	-	69	-	-	-	29	-	-	-
Common Stock Shares Outstanding	113,756	106,568	113,674	113,986	113,531	111,986	109,265	109,041	108,957	107,843	107,735	106,680	105,838	106,316	106,730	106,535	106,567	107,045	105,929	102,748	102,738	102,642	102,596	102,557	91,452	84,798	83,906	82,972	82,900	82,871	82,871	82,860	82,795	82,470	82,038	76,039	76,039	67,169	66,168	54,139	54,139	44,686	41,445	41,421	41,421	32,133	26,851	24,710	24,710	21,655	21,655	19,922	19,922	18,822	18,043	18,043	18,043	14,065	14,065	14,065	14,065	12,863	12,567	12,553	12,553	12,528	12,528	12,519	12,519	7,021	6,888	6,888	6,205	6,205	5,497	5,497	2,918	2,918	2,918	2,918
Common Stock Total Equity	0	0	0	106	105	104	103	103	103	103	103	104	104	104	103	103	103	103	103	103	103	103	103	103	103	85	85	83	83	83	83	83	83	83	82	82	69	67	67	54	54	54	41	41	41	35	31	25	25	22	22	22	19	19	18	18	18	14	14	14	14	14	13	13	13	13	13	13	13	7	69	-	69	-	-	-	29	-	-	-
Current Deferred Revenue	729	52,473	47,274	0	0	0	0	0	23,744	17,474	12,899	11,642	18,364	16,042	14,177	15,842	19,508	13,010	10,381	5,638	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Intangible Assets	194,049	167,108	175,595	184,083	32,471	33,051	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Inventory	15,644	9,035	10,751	10,328	6,805	7,132	7,850	7,827	7,870	6,950	7,097	4,390	4,651	4,748	1,828	2,211	1,957	600	270	97	56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	823	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Liabilities And Stockholders Equity	471,907	413,211	443,896	407,227	375,630	333,114	267,309	246,972	237,788	223,248	209,130	197,216	192,354	174,860	131,412	117,880	112,376	96,691	78,234	61,077	60,450	67,710	74,288	79,128	85,387	34,631	35,980	37,697	41,707	45,313	48,941	53,666	60,102	64,563	68,337	76,050	43,908	45,845	45,929	22,230	25,370	28,695	12,545	16,789	16,789	12,105	7,704	4,989	6,249	4,298	5,610	7,156	5,831	6,415	5,911	7,037	7,966	5,078	6,481	9,248	12,033	15,348	13,535	15,489	16,680	17,593	18,247	20,619	20,619	3,512	365	-	789	-	-	-	185	-	-	-
Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	875	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Long Term Investments	16,489	12,897	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5,009	5,008	4,992	5,008	5,019	5,005	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Net Debt	-134,079	-117,328	-175,058	-144,779	-294,501	-252,092	-206,861	-174,243	-167,551	-150,585	-131,044	-123,077	-130,208	-116,991	-114,854	-100,876	-88,864	-43,963	-22,328	-18,207	-16,559	-10,616	-9,888	-19,601	-57,497	-7,329	-8,584	-9,981	-13,893	-17,638	-18,717	-22,228	-28,235	-32,750	-37,221	-41,323	-9,097	-11,264	-14,802	-1,072	-2,216	-12,963	-879	-1,410	-1,410	-11,974	-7,515	-4,723	-6,029	-2,151	-3,406	-6,873	-5,475	-6,247	-5,608	-6,758	-7,779	-4,912	-6,266	-8,930	-11,767	-15,027	-13,084	-14,717	-15,944	-16,886	-17,600	-20,435	-20,435	-3,003	-324	-	-771	-	-	-	-184	-	-	-
Net Invested Capital	387,881	348,548	375,294	333,661	300,421	270,041	241,092	220,221	206,831	198,661	188,944	178,651	169,598	156,628	111,201	99,676	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Net Receivables	53,514	48,049	42,796	33,402	10,439	9,661	9,804	10,784	6,619	6,822	9,209	6,005	5,987	6,179	6,762	6,919	10,537	10,095	10,376	7,251	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,500	3,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	134	134	0	0	0	0	0	0	3	12	17	24	41	64	66	79	86	86	0	0	-	0	-	-	-	0	-	-	-
Net Tangible Assets	0	0	199,699	149,578	267,950	236,990	241,092	220,221	206,831	198,661	188,944	178,651	169,598	156,628	111,201	99,676	87,630	77,983	63,282	51,176	50,784	64,077	71,062	76,246	80,964	31,729	33,969	35,096	39,309	42,903	46,325	50,537	55,476	60,650	62,792	66,622	35,242	36,623	41,188	17,638	21,391	22,119	9,844	12,920	14,622	9,395	6,411	2,717	3,761	3,875	4,954	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Net Working Capital	143,266	134,211	188,465	142,202	263,209	231,629	220,070	198,253	183,043	172,181	160,170	147,097	136,488	125,110	110,953	99,308	87,265	72,597	57,904	45,836	45,676	59,013	66,004	76,205	80,921	31,679	33,913	35,551	39,359	43,060	46,368	50,815	56,461	61,970	65,711	70,121	37,973	39,825	43,491	19,731	23,180	25,628	10,847	15,080	15,080	11,332	7,005	4,086	5,394	3,846	4,918	6,238	5,476	5,960	5,394	6,630	7,593	4,728	5,919	7,609	10,485	13,997	12,656	14,905	16,228	17,043	17,758	19,815	19,815	2,320	-108	-	429	-	-	-	116	-	-	-
Non Current Assets Total	252,578	221,194	202,928	208,316	54,833	56,804	24,751	25,781	27,682	30,453	32,825	35,683	33,110	31,518	248	936	1,013	6,111	6,178	6,215	5,263	5,229	5,201	192	200	214	227	240	253	258	267	187	200	207	72	80	80	80	74	62	50	55	61	63	63	20	22	23	21	29	36	55	56	60	66	72	79	84	91	101	118	130	138	146	148	146	70	32	0	505	38	-	18	-	-	-	1	-	-	-
Non Current Liabilities Other	485	431	12,723	16,857	17,621	18,392	3,729	3,813	3,894	3,973	4,051	4,129	0	0	0	568	648	726	1,603	875	155	165	143	150	157	165	171	695	303	414	310	465	1,185	1,527	2,991	3,578	2,811	3,283	2,377	2,155	1,839	3,564	1,063	565	520	1,957	616	1,393	1,655	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Non Current Liabilities Total	7,963	6,857	16,099	16,857	17,621	18,392	3,729	3,813	3,894	3,973	4,051	4,129	0	0	0	568	648	726	801	875	155	165	143	150	157	165	171	695	303	414	310	465	1,185	1,527	2,991	3,578	2,811	3,283	2,377	2,155	1,839	3,564	1,063	520	520	1,957	616	1,393	1,655	0	0	11	15	19	47	47	54	50	36	40	43	46	49	51	54	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Non Currrent Assets Other	0	0	-179,439	-188,074	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	11	11	11	11	11	11	11	11	11	11	13	21	25	25	25	20	20	20	12	12	486	24	-	14	-	-	-	0	-	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Other Assets	0	0	23,489	0	18,745	20,038	20,939	21,899	23,706	26,409	28,710	31,430	32,980	31,356	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	11	11	10	11	11	11	11	11	11	11	13	22	25	25	25	20	20	20	20	11	485	24	-	13	-	-	-	0	-	-	-
Other Current Assets	12,535	352	361	6,934	5,158	466	394	433	4,351	228	321	276	8,328	590	292	327	4,351	431	382	1,881	1,650	191	677	52	1,174	50	34	57	1,048	36	35	36	1,505	53	861	109	34	45	32	59	23	24	10	15	7,812	112	167	243	199	2,004	2,002	228	166	109	237	207	108	82	125	214	136	173	288	585	524	496	498	67	67	3	3	-	0	-	-	-	0	-	-	-
Other Current Liab	60,170	374	455	52,973	53,276	41,822	19,851	17,483	243	110	112	111	107	70	31	140	172	531	153	166	7,174	2,127	2,159	1,926	2,321	1,656	1,148	988	1,161	940	1,598	1,412	1,646	1,569	1,237	4,798	4,041	5,414	1,126	1,505	1,289	1,538	1,189	281	282	397	454	529	570	9	178	437	193	155	199	246	45	103	195	799	1,097	585	559	122	83	176	272	325	324	269	409	-	275	-	-	-	37	-	-	-
Other Liab	0	0	12,723	0	14,064	14,749	0	0	0	0	0	0	0	0	0	0	0	0	0	0	155	165	143	150	157	164	171	695	303	414	311	465	1,185	1,527	2,992	3,578	2,811	3,283	2,377	2,155	1,839	3,564	1,063	565	520	1,957	616	1,393	1,654	0	0	11	14	19	48	47	54	49	36	40	43	45	49	51	54	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Other Stockholder Equity	266,488	261,998	257,976	254,114	250,430	245,514	239,476	236,191	233,186	231,165	226,699	224,927	223,168	221,673	219,582	217,751	216,206	214,478	213,405	212,288	211,265	210,084	209,222	208,426	207,581	152,969	151,019	148,255	147,488	146,907	146,365	145,999	145,539	144,927	142,652	141,915	105,129	103,013	102,562	75,821	75,763	75,131	56,951	56,830	0	51,530	45,926	41,946	41,898	39,745	39,689	39,602	37,321	37,069	35,572	35,480	35,390	31,370	31,287	31,215	31,065	30,830	26,632	26,501	26,231	26,144	26,047	25,600	0	7,842	3,562	-	3,408	-	-	-	1,312	-	-	-
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	-	1	-	-	-	1	-	-	-
Property Plant And Equipment Gross	4,426	4,400	4,401	3,991	3,617	4,087	0	0	0	0	4,115	4,253	130	161	239	927	1,004	1,093	1,161	1,214	245	201	187	183	191	205	218	231	244	249	259	178	192	198	63	71	71	71	65	53	41	46	52	54	54	11	14	14	12	18	26	45	46	49	55	62	68	73	81	88	96	105	113	121	128	126	50	20	20	20	14	-	4	-	-	-	1	-	-	-
Property Plant And Equipment Net	3,703	3,761	3,844	3,991	3,617	3,715	3,812	3,882	3,976	4,044	4,115	4,253	130	161	239	927	1,004	1,093	1,161	1,214	245	201	187	183	191	205	218	231	244	249	259	178	192	198	63	71	71	71	65	53	41	46	52	54	0	11	14	14	12	18	26	45	46	49	55	62	68	73	81	88	96	105	113	121	128	126	50	20	0	20	14	-	4	-	-	-	1	-	-	-
Property Plant Equipment	0	0	3,844	1,285	847	882	917	925	3,976	951	4,115	944	130	149	168	197	210	141	148	140	245	201	187	183	191	205	218	231	244	249	259	178	192	198	63	71	71	71	65	53	41	46	52	58	54	11	14	14	12	18	26	45	45	48	55	62	68	73	80	89	96	105	113	121	128	125	50	23	20	20	14	-	4	-	-	-	1	-	-	-
Retained Earnings	121,272	86,428	117,192	79,430	49,862	24,391	1,643	-15,620	-26,310	-32,544	-37,821	-46,335	-53,706	-65,143	-108,483	-118,263	-128,689	-136,618	-150,249	-161,208	-160,564	-146,064	-138,225	-132,260	-126,560	-121,173	-116,995	-113,115	-108,148	-103,985	-100,031	-95,462	-90,076	-84,260	-79,811	-75,253	-69,843	-66,353	-61,343	-58,145	-54,334	-52,979	-47,067	-42,179	-42,179	-42,102	-39,481	-39,192	-38,103	-35,751	-34,623	-33,229	-31,712	-30,983	-30,079	-28,750	-27,705	-26,543	-25,256	-23,495	-20,463	-16,716	-13,860	-11,483	-9,899	-8,954	-8,219	-5,759	-5,759	-5,018	-3,697	-	-3,030	-	-	-	-1,224	-	-	-
Retained Earnings Total Equity	0	0	0	79,430	49,862	24,391	1,643	-15,620	-26,310	-32,544	-37,821	-46,335	0	-65,143	-108,483	-118,263	-128,689	-136,618	-150,249	-161,208	-160,564	-146,064	-138,225	-132,260	-126,560	-121,173	-116,995	-113,115	-108,148	-103,985	-100,031	-95,462	-90,076	-84,260	-79,811	-75,253	-69,843	-66,353	-61,343	-58,145	-54,334	-52,979	-47,067	-43,923	-42,179	-42,102	-39,481	-39,192	-38,103	-35,751	-34,623	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	283	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Short Long Term Debt Total	3,557	3,643	3,729	3,468	3,894	3,973	4,051	4,129	3,894	4,251	4,251	4,251	29	115	198	875	648	1,020	1,090	875	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Short Term Debt	369	361	353	345	337	330	322	316	308	278	200	122	29	115	198	307	301	294	288	283	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	235	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Short Term Investments	0	0	0	0	0	0	9,876	19,424	19,821	19,956	19,980	15,971	10,041	10,003	0	5,007	5,007	31,562	36,503	26,551	36,922	51,048	58,521	58,343	26,517	26,578	26,548	26,546	26,513	27,106	29,305	30,227	30,161	30,212	30,182	30,214	30,178	30,183	30,211	20,212	21,495	14,688	10,491	14,007	14,007	0	0	0	0	2,004	2,002	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Total Assets	471,907	413,211	443,896	407,227	375,630	333,114	267,309	246,972	237,788	223,248	209,130	197,216	192,354	174,860	131,412	117,880	112,376	96,691	78,234	61,077	60,450	67,710	74,288	79,128	85,387	34,631	35,980	37,697	41,707	45,313	48,941	53,666	60,102	64,563	68,337	76,050	43,908	45,845	45,929	22,230	25,370	28,695	12,545	16,789	16,789	12,105	7,704	4,989	6,249	4,298	5,610	7,156	5,831	6,415	5,911	7,037	7,966	5,078	6,481	9,248	12,033	15,348	13,535	15,489	16,680	17,593	18,247	20,619	20,619	3,512	365	-	789	-	-	-	185	-	-	-
Total Current Assets	219,329	192,017	240,968	198,911	320,797	276,310	242,558	221,191	210,106	192,795	176,305	161,533	159,244	143,342	131,164	116,944	111,364	90,579	72,056	54,862	55,187	62,481	69,086	78,936	85,187	34,417	35,753	37,457	41,454	45,055	48,673	53,479	59,901	64,356	68,265	75,970	43,828	45,764	45,855	22,168	25,320	28,640	12,484	16,727	16,727	12,085	7,682	4,966	6,228	4,269	5,574	7,101	5,775	6,356	5,845	6,964	7,887	4,994	6,390	9,146	11,915	15,218	13,397	15,343	16,532	17,448	18,177	20,588	20,588	3,007	327	-	772	-	-	-	184	-	-	-
Total Current Liabilities	76,063	57,806	52,503	56,709	57,588	44,681	22,488	22,938	27,063	20,614	16,135	14,436	22,756	18,232	20,210	17,636	24,099	17,982	14,152	9,026	9,511	3,468	3,082	2,731	4,266	2,738	1,840	1,906	2,095	1,996	2,305	2,664	3,441	2,386	2,553	5,849	5,855	5,939	2,364	2,437	2,140	3,012	1,638	1,647	1,647	753	677	879	834	423	656	862	299	396	451	335	294	266	471	1,537	1,430	1,221	740	438	303	405	418	773	773	687	434	-	343	-	-	-	68	-	-	-
Total Liab	84,026	64,663	68,602	73,566	75,209	63,073	26,217	26,751	30,957	24,587	20,186	18,565	22,756	18,232	20,210	18,204	24,746	18,708	14,953	9,901	9,666	3,633	3,225	2,882	4,424	2,902	2,011	2,601	2,398	2,410	2,616	3,129	4,625	3,913	5,545	9,427	8,666	9,222	4,741	4,591	3,978	6,576	2,701	2,167	2,167	2,710	1,293	2,272	2,489	423	656	873	314	415	499	381	349	315	507	1,576	1,473	1,266	789	489	357	405	418	773	773	687	434	-	343	-	-	-	68	-	-	-
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Total Stockholder Equity	387,881	348,548	375,294	333,661	300,421	270,041	241,092	220,221	206,831	198,661	188,944	178,651	169,598	156,628	111,201	99,676	87,630	77,983	63,282	51,176	50,784	64,077	71,062	76,246	80,964	31,729	33,969	35,096	39,309	42,903	46,325	50,537	55,476	60,650	62,792	66,622	35,242	36,623	41,188	17,638	21,391	22,119	9,844	14,622	14,622	9,395	6,411	2,717	3,761	3,875	4,954	6,283	5,518	6,001	5,412	6,655	7,618	4,763	5,974	7,671	10,560	14,082	12,746	15,000	16,323	17,188	17,828	19,847	19,847	2,825	-69	-	446	-	-	-	118	-	-	-
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Begin Period Cash Flow	298,395	171,445	130,237	89,512	16,559	57,497	13,893	28,235	9,097	2,216	1,410	6,029	5,475	7,779	11,767	15,944	20,435	771	184	416
Capital Expenditures	198,524	29	1,021	11	19	92	92	96	23	57	9	52	4	3	2	1	66	21	4	2
Cash And Cash Equivalents Changes	0	126,950	41,208	0	72,952	-40,937	43,604	-14,342	19,138	6,881	806	-4,619	554	0	0	0	0	0	0	0
Cash Flows Other Operating	0	4,042	5,128	0	-3,026	-476	-126	457	-452	-2,943	-300	-2,240	-31	0	0	0	0	0	0	0
Change In Cash	-160,759	126,950	41,208	40,725	72,952	-40,937	43,604	-14,342	19,138	6,881	806	-4,619	554	-2,304	-3,987	-4,177	-4,491	19,664	587	-232
Change In Working Capital	-37,324	13,729	5,022	-4,111	-1,096	4,710	2,029	-884	663	769	190	-285	627	-227	-1,073	1,554	-858	325	176	14
Change Receivables	0	-3,820	-632	0	-10,537	0	0	0	0	0	0	0	134	0	0	0	0	0	0	0
Change To Account Receivables	-43,075	-3,820	-632	4,550	-10,537	-10,537	-10,537	-10,537	0	0	0	0	134	0	12	51	22	0	0	0
Change To Inventory	-4,739	1,065	-3,219	-2,694	-1,901	-56	-56	-56	-56	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	17,598	4,032	139	14,320	5,243	2,155	-1,341	1,115	3,712	490	825	524	0	0	0	0	475	190	14
Change To Netincome	0	12,844	15,389	-25,929	3,825	3,551	2,595	950	1,520	1,772	2,066	340	737	0	0	0	0	0	0	0
Change To Operating Activities	0	15,277	10,361	-6,105	9,562	4,375	1,017	-23	683	-195	0	0	0	0	0	0	0	0	0	0
Depreciation	33,143	1,239	192	885	298	38	46	43	34	27	22	11	43	26	30	33	16	5	1	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	137,636	298,395	171,445	130,237	89,512	16,559	57,497	13,893	28,235	9,097	2,216	1,410	6,029	5,475	7,779	11,767	15,944	20,435	771	184
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-54,924	116,018	59,351	45,023	34,592	-25,796	-13,743	-18,060	-18,039	-12,999	-9,885	-5,193	-4,989	-3,760	-7,685	-8,262	-4,491	-1,200	-459	-232
Investments	-255,184	19,238	-10,000	-5,011	37,244	-15,434	-4	3,649	17	-8,684	-9,979	-14,007	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	0	0	0	0	0	0	0	5,000	0	0	0	0	0	0	0	0
Net Income	71,410	83,079	39,482	74,983	31,875	-34,004	-18,412	-18,072	-20,233	-15,509	-12,155	-4,076	-6,391	-4,006	-7,242	-10,565	-4,139	-2,729	-1,805	-540
Other Cashflows From Financing Activities	-13,649	4,502	-153	0	1,116	293	3,578	-34,805	2,286	1,839	4,107	5,016	-4	-3	-2	-1	-66	-21	-4	-2
Other Cashflows From Investing Activities	0	-10,000	0	0	37,244	-15,434	-4	3,649	17	0	2,491	0	0	0	0	0	0	0	0	0
Other Non Cash Items	79,939	5,156	287	-12	-291	39,955	187	-886	1,585	994	2,066	340	320	450	601	718	556	1,221	1,173	295
Sale Purchase Of Stock	0	-6,907	-12,089	-56	1,116	298	57,350	80	37,160	28,564	18,178	9,581	5,543	0	0	-3	0	0	0	0
Stock Based Compensation	14,250	7,907	6,073	6,261	3,825	3,551	2,408	1,836	1,585	778	176	340	417	450	601	718	556	1,221	0	0
Total Cash From Financing Activities	-10,857	1,694	-8,143	702	1,116	293	57,350	69	37,160	28,564	18,178	14,581	5,543	1,456	3,698	4,084	0	20,863	1,047	0
Total Cash From Operating Activities	143,600	116,047	60,372	45,035	34,611	-25,704	-13,743	-17,964	-18,015	-12,942	-9,876	-5,140	-4,985	-3,757	-7,683	-8,260	-4,425	-1,179	-455	-231
Total Cashflows From Investing Activities	0	9,209	-11,021	-5,011	37,225	-15,526	-4	3,553	-6	-8,741	-7,497	-14,060	-4	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2005-12-31	2004-12-31
Begin Period Cash Flow	120,971	178,787	148,247	298,395	256,065	210,912	178,372	171,445	154,836	135,295	127,328	130,237	117,106	115,052	101,751	89,512	44,983	23,418	19,082	16,559	10,616	9,888	19,601	57,497	7,329	8,584	9,981	13,893	17,638	18,717	22,228	28,235	32,750	37,221	41,323	9,097	11,264	14,802	1,072	2,216	12,963	879	646	11,974	11,974	7,515	4,723	6,029	2,151	3,406	6,873	5,475	6,247	5,608	6,758	7,779	4,912	6,266	8,930	11,767	15,027	13,084	14,717	15,944	16,886	17,600	19,065	3,003	3,003	324	0	0	0
Capital Expenditures	36,093	79,352	2,559	74	992	29	29	29	41	68	1	911	19,369,000	11	11	11	0	19	14	6	57	23	12	12	-14	-13	-13	7	7	0	89	-13	23	14	1	8	14	13	13	17	9	9	0	46	46	0	2	5	2	2	2	0	3	-7	-7	-6	2	-7	-9	-7	1	1	1	1	10	22	30	1	1	7	12	4	1
Cash And Cash Equivalents Changes	0	0	0	-150,148	42,330	45,153	32,540	6,927	16,609	19,541	7,967	-2,909	0	2,054	13,301	12,239	44,528	21,566	4,336	2,522	5,943	728	-9,713	-37,896	50,168	-1,255	-1,397	-3,912	-3,745	-1,079	-3,511	-6,007	-4,515	-4,471	-4,102	32,227	-2,167	-3,538	13,729	-1,143	-10,747	12,084	233	-764	-10,564	4,459	2,792	-1,306	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	0	-79	-1,397	4,807	1,210	-578	79	3,318	710	1,021	0	1,875	-1,562	-1,640	-1,127	-1,967	308	-239	-833	-139	315	181	-663	111	308	118	-737	340	373	481	-111	-533	71	120	-235	-3,475	41	726	-621	-418	627	112	-2,328	55	76	-44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	16,665	-57,816	30,540	-150,148	42,330	45,153	32,540	6,927	16,609	19,541	7,967	-2,909	13,131	2,054	13,301	12,239	44,528	21,566	4,336	2,522	5,943	728	-9,713	-37,896	50,168	-1,255	-1,397	-3,912	-3,745	-1,079	-3,511	-6,007	-4,515	-4,471	-4,102	32,227	-2,167	-3,538	13,729	-1,143	-10,747	12,084	233	-10,564	-10,564	4,459	2,792	-1,306	3,878	-1,255	-3,467	1,398	-772	639	-1,149	-1,022	2,867	-1,353	-2,664	-2,837	-3,261	1,943	-1,632	-1,227	-942	-714	-1,465	17,431	17,431	2,679	0	0	0
Change In Working Capital	7,654	-3,611	-15,702	-25,665	10,717	10,682	989	-8,659	5,537	7,429	-883	-7,061	1,792	-2,100	1,088	-4,890	3,228	1,856	2,146	-8,325	5,144	268	659	-1,361	865	1,002	238	-76	-642	27	12	-282	991	-714	274	112	-314	98	-38	1,022	-1,494	1,499	782	-305	3,748	132	-126	14	337	-181	-155	626	-293	44	87	-66	7	-149	-975	44	612	222	631	88	-74	-56	-411	-88	17,495	424	-536	312	0
Change Receivables	0	0	0	-22,963	-1,102	250	965	-3,933	6	-333	-691	386	0	890	156	3,618	-442	281	-3,125	-7,251	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-5,465	-5,253	-9,394	-22,963	-1,102	250	965	-3,933	6	-333	-691	386	-116	890	156	3,618	-442	281	-3,125	-7,251	-7,251	-7,251	-7,251	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	134	134	134	134	0	0	0	0	12	12	12	9	51	47	40	23	22	20	7	0	0	0	0	0	0
Change To Inventory	-6,609	1,716	-423	577	327	718	-23	43	-920	147	-2,707	261	97	-2,920	383	-255	-1,357	-330	-173	-41	-56,012,000	-56	-56	-56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	1,030	-3,006	12,952	9,236	-457	-4,133	6,452	4,402	365	-8,735	2,251	-1,895	2,684	-6,469	6,110	3,825	5,120	-734	6,033	408	344	-1,542	1,529	891	-71	-194	95	-313	-361	-763	1,102	-182	203	-8	-78	3,574	-79	296	-873	1,373	654	-664	893	77	-202	58	0	0	372	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	475	416	1	190	14
Change To Netincome	0	0	124	1,373	3,211	2,989	2,840	3,804	4,217	3,813	4,346	3,121	-143	-29,870	1,794	1,519	1,149	817	925	933	1,030	758	792	971	486	530	428	1,151	382	639	204	-275	187	-191	30	1,495	-184	1,351	246	359	-1,288	3,267	45	42	494	-1,295	1,370	-229	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	-6,915	-6,915	10,046	9,500	2,871	-7,140	6,435	7,787	2,150	-6,011	-440	3,728	-3,909	-5,484	5,056	1,086	5,056	-1,636	4,204	-150	541	-220	1,017	613	308	118	-23	340	373	481	683	0	0	0	-195	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	9,143	8,568	8,570	6,600	615	553	37	34	33	31	31	97	31	89	688	77	271	7	6	14	12	9	8	8	7	13	13	13	12	9	9	13	6	11	9	8	8	7	6	5	6	6	6	3	3	3	3	3	8	7	21	6	6	6	6	7	7	7	8	8	8	8	8	8	8	3	3	1	1	2	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	137,636	120,971	178,787	148,247	298,395	256,065	210,912	178,372	171,445	154,836	135,295	127,328	130,237	117,106	115,052	101,751	89,512	44,983	23,418	19,082	16,559	10,616	9,888	19,601	57,497	7,329	8,584	9,981	13,893	17,638	18,717	22,228	28,235	32,750	37,221	41,323	9,097	11,264	14,802	1,072	2,216	12,963	879	1,410	1,410	11,974	7,515	4,723	6,029	2,151	3,406	6,873	5,475	6,247	5,608	6,758	7,779	4,912	6,266	8,930	11,767	15,027	13,084	14,717	15,944	16,886	17,600	20,435	20,435	3,003	324	0	0
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	19,555	-34,224	30,754	11,996	39,085	41,272	26,162	8,478	19,135	21,639	15,674	2,903	-19,355,894	11,440	13,265	7,213	12,291	16,263	14,006	-7,968	-8,370	-6,826	-4,506	-6,081	-4,030	-2,633	-3,201	-3,879	-4,419	-3,278	-4,344	-5,930	-4,655	-5,358	-4,247	-3,803	-3,994	-3,566	-2,997	-2,442	-4,121	-1,684	-1,812	-1,639	-1,639	-1,101	-1,146	-1,306	-1,440	-1,253	-1,463	-831	-769	-817	-1,149	-1,022	-831	-1,353	-2,664	-2,837	-2,901	-2,520	-1,615	-1,225	-942	-714	-1,465	-679	-679	-74	0	0	0
Investments	-38,318	-92,817	0	-162,367	0	9,868	9,370	9,370	-41	-68	-4,000	-6,000	-6,000	-10,000	-10,000	5,000	31,659	5,047	-9,863	10,401	14,162	7,450	-68,894	31,848	61	-30	-2	-33	594	2,199	922	-66	50	-30	32	-35	5	326	-9,998	984	-6,805	-4,195	-473	1,495	-14,007	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	34,844	-30,764	37,762	29,568	25,471	22,748	21,619	13,241	9,309	10,329	12,181	7,663	11,437	43,340	9,780	10,426	7,930	13,630	10,960	-645	-14,500	-7,839	-5,965	-5,700	-5,388	-4,178	-3,880	-4,967	-4,163	-3,954	-4,569	-5,386	-5,815	-4,449	-4,559	-5,410	-3,490	-5,010	-3,198	-3,811	-1,355	-5,912	-3,144	-77	-77	-2,622	-289	-1,089	-2,352	-1,128	-1,394	-1,517	-729	-904	-1,329	-1,045	-1,162	-1,287	-1,762	-3,031	-3,748	-2,855	-2,377	-1,584	-945	-734	-1,208	-741	-741	-1,321	0	0	0
Other Cashflows From Financing Activities	-1,887	-10,339	-779	-644	-3,571	6,907	1,364	1,000	-209	2,955	-3,707	-105	-1,116,241,974	614	36	26	-538	256	193	89	-297,562,849	105	4	33	54,137	1,408	1,805	-33	-34,805	2,199	833	-66	65	917	113	1,191	-26,725,101,453	15	-10,012	17	-14,071,679,739	3,893	24	5,016	5,016	0	-2	-5	2,002	-2	0	-3	-3	0	0	-2	-2	0	0	20	17	4,464	-17	-2	-10	-22	-30	472	472	2,753	0	0	0
Other Cashflows From Investing Activities	0	0	0	-162,293	0	-10,000	0	0	0	0	0	0	0	0	0	5,000	37,244	5,585	538	10,401	-15,434	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1	299	-1	-2	2,495	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-1,126	81,068	65	194	63	4,329	706	58	80	105	108	-6	-1	-8	-85	81	-287	-47	-17	60	4,710,486,000	0	0	486	486	0	-210	397	-107	107	-153	-733	576	-522	-334	1,180	-472	907	224	336	-1,288	2,723	45	-1,496	204	-1,281	-1,066	-1,363	4,359	-1,128	-1,394	54	-1,073	36	86	82	-1,073	75	65	142	226	105	123	263	79	94	182	151	151	829	0	0	0
Sale Purchase Of Stock	529	0	-52	-477	1,725	-6,907	-4,356	-2,551	-3,075	-5,053	-3,961	293	0	631	36	26	578	256	193	89	151	105	9	33	54,137	1,408	1,805	0	11	0	0	-11	65	917	113	36,065	1,822	0	26,725	17	190	17,965	24	0	83	5,560	3,938	0	0	2,229	2,229	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	4,250	3,810	3,298	2,892	1,926	2,055	2,023	1,903	1,472	1,512	1,518	1,571	1,469	1,478	1,794	1,519	1,149	817	925	933	1,030	758	792	971	486	530	639	754	489	532	357	458	576	331	364	314	288	445	23	23	43	47	45	204	0	46	45	45	249	49	65	54	246	36	86	82	319	75	65	142	718	0	0	263	556	0	0	200	0	0	0	0	0
Total Cash From Financing Activities	-665	-10,127	-214	149	2,253	3,984	-2,992	-1,551	-2,526	-2,098	-3,707	188	26	614	36	26	578	256	193	89	151	105	4	33	54,137	1,408	1,805	80	80	-11	-11	-11	65	917	113	36,065	1,822	26,742	26,725	17	190	17,965	24	5,083	5,083	5,560	3,938	3,314	3,314	2,229	2,229	2,229	3,698	1,456	0	3,698	3,698	0	0	-360	-360	4,464	-17	-2	0	0	0	18,110	18,110	2,753	0	1,046	0
Total Cash From Operating Activities	55,648	45,128	30,754	12,070	40,077	41,301	26,191	8,478	19,176	21,707	15,675	3,814	13,106	11,451	13,265	7,213	12,291	16,263	14,020	-7,963	-8,314	-6,803	-4,506	-6,081	-4,030	-2,633	-3,201	-3,879	-4,412	-3,278	-4,344	-5,930	-4,631	-5,343	-4,246	-3,795	-3,980	-3,553	-2,984	-2,425	-4,130	-1,684	-1,812	-1,594	-1,594	-1,101	-1,144	-1,301	-1,438	-1,253	-1,463	-831	-769	-817	-1,149	-1,022	-829	-1,353	-2,664	-2,837	-2,901	-2,520	-1,615	-1,224	-932	-692	-1,435	-678	-678	-66	0	0	0
Total Cashflows From Investing Activities	0	0	0	-162,367	0	-132	9,341	9,341	-41	-68	-4,001	-6,911	-6,911	-10,011	-10,011	5,000	31,659	5,047	-9,877	10,396	14,105	7,427	-5,210	-31,848	61	-30	-2	-33	586	2,199	833	-66	50	-44	31	-43	-9	15	-10,012	1,265	-6,807	-4,197	2,022	1,485	-14,053	0	-2	-5	-4	-2,006	-2,003	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31
Cost Of Revenue	84,532	34,393	21,884	17,039	14,759	19,919	11,375	0	0	0	0	0	6,039	4,487	0	0	0	0	0	0	-	-
Depreciation And Amortization	33,143	1,239	192	885	298	38	46	43	34	27	22	11	43	26	30	33	16	5	1	0	-	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Ebit	86,812	101,838	52,385	41,303	31,823	-35,295	-18,538	-20,210	-20,498	-13,598	-8,421	-6,362	-5,762	-4,024	-7,275	-10,894	-5,027	-2,902	-1,822	-543	-429	-256
Ebitda	119,955	103,077	52,577	42,188	32,121	-35,257	-18,493	-20,166	-20,463	-13,571	-8,399	-6,351	-5,719	-3,998	-7,245	-10,861	-5,011	-2,897	-1,821	-543	-429	-256
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Gross Profit	313,672	179,810	118,949	102,034	87,547	500	-11,375	0	0	0	0	0	0	489	0	0	0	0	0	0	-	-
Income Before Tax	94,511	104,719	52,667	41,890	33,409	-34,004	-18,412	-18,072	-20,233	-15,509	-12,155	-4,076	-6,391	-4,006	-7,242	-10,565	-4,139	-2,729	-1,805	-540	-	-256
Income Tax Expense	23,101	21,640	13,185	-33,093	1,534	2,583	141	-930	-99	994	1,843	-1,156	309	0	0	0	0	0	0	0	429	-
Interest Expense	0	4,120	474	1,472	1,884	1,292	454	322	100	76	47	15	11	18	33	329	0	0	0	0	0	0
Interest Income	0	0	0	0	1,586	1,292	454	322	65	0	0	0	0	0	0	0	0	0	0	0	-	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Income	71,410	83,079	39,482	74,983	31,875	-34,004	-18,412	-18,072	-20,233	-15,509	-12,155	-4,076	-6,391	-4,006	-7,242	-10,565	-4,139	-2,729	-1,805	-540	-429	-256
Net Income Applicable To Common Shares	0	83,079	39,482	74,983	31,875	-34,004	-18,412	-18,072	-20,233	-15,509	-12,155	-4,076	-6,391	0	0	0	0	0	0	0	-	-
Net Income From Continuing Ops	62,037	83,079	39,482	74,983	31,875	-34,004	-18,412	-18,072	-20,233	-15,509	-12,155	-4,076	-6,391	0	0	0	0	0	0	0	-	-
Net Interest Income	0	0	0	0	1,586	1,292	454	322	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Non Operating Income Net Other	0	2,881	282	0	1,586	1,292	267	1,208	165	-918	-1,843	1,145	-309	0	0	0	0	0	0	0	-	-
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Operating Income	86,812	101,838	52,385	41,303	31,823	-35,295	-18,680	-19,280	-20,398	-14,591	-10,312	-5,221	-6,082	-4,024	-7,275	-10,894	-5,027	-2,902	-1,822	-543	-429	-256
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Operating Expenses	311,392	112,365	88,448	77,770	70,483	35,795	18,680	19,280	20,398	14,591	10,312	5,221	6,082	4,513	7,275	10,894	5,027	2,902	1,822	543	429	256
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Reconciled Depreciation	24,353	1,239	192	885	298	38	46	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Research Development	93,150	19,789	16,936	16,497	18,843	19,919	11,375	11,370	11,801	10,118	8,097	2,660	3,384	2,307	5,097	8,710	2,991	989	1,463	378	-	138
Selling And Marketing Expenses	86,689	29,469	26,151	23,567	3,300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Selling General Administrative	47,021	28,714	23,477	20,667	36,881	15,876	7,304	7,910	8,597	4,474	2,215	2,562	2,698	2,206	2,178	2,184	2,036	1,913	1,821	543	-	-
Tax Provision	18,775	21,640	13,185	-33,093	1,534	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Operating Expenses	226,860	77,972	66,564	60,730	55,724	35,795	18,680	19,280	20,398	14,591	10,312	5,221	6,082	4,513	7,275	10,894	5,027	2,902	1,822	543	-429	256
Total Other Income Expense Net	7,699	2,881	282	587	1,586	1,292	267	1,208	165	-918	-1,890	1,130	-320	18	33	329	888	173	17	3	-	-
Total Revenue	398,204	214,203	140,833	119,073	102,306	500	0	0	0	0	0	0	0	489	0	0	0	0	0	0	-	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31
Cost Of Revenue	24,868	14,167	12,045	9,946	11,195	9,665	7,643	5,890	7,348	5,310	4,545	4,681	4,870	3,879	4,140	4,151	4,398	4,387	4,262	1,712	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,026	1,124	1,376	1,513	1,214	902	1,328	1,043	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Depreciation And Amortization	9,143	8,568	8,570	6,531	615	553	37	34	33	31	31	97	31	89	688	77	271	7	6	14	12	9	8	8	7	13	13	13	12	9	9	13	6	11	9	8	8	7	6	5	6	6	6	3	3	3	3	3	8	7	21	6	6	6	6	7	7	7	8	8	8	8	8	8	8	3	3	1	1	2	0	-	0	-	-	-	0	-	-	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Ebit	41,692	-37,188	46,699	35,609	30,186	25,102	28,569	17,366	12,709	14,004	15,838	9,801	8,586	11,704	10,282	10,700	7,736	13,845	10,959	-1,002	-14,856	-8,183	-6,344	-5,933	-5,519	-4,307	-4,392	-4,283	-4,433	-3,807	-4,967	-6,971	-6,587	-5,539	-5,240	-3,112	-4,456	-3,202	-2,767	-3,173	-4,037	-569	-2,155	-2,925	-1,505	57	-1,844	-1,639	-2,034	-1,131	-1,397	-1,519	-732	-908	-1,333	-1,050	-1,170	-1,292	-1,769	-3,045	-3,791	-2,915	-2,464	-1,724	-1,143	-950	-1,437	-885	-885	-1,342	-333	0	0	0	0	-	0	-	-	-
Ebitda	50,835	-28,620	55,269	42,140	30,801	25,655	28,606	17,400	12,742	14,035	15,869	9,898	8,618	11,793	10,970	10,776	8,007	13,852	10,966	-988	-14,843	-8,173	-6,336	-5,925	-5,512	-4,294	-4,379	-4,270	-4,421	-3,798	-4,958	-6,958	-6,581	-5,528	-5,231	-3,103	-4,448	-3,195	-2,760	-3,168	-4,031	-563	-2,149	-2,922	-1,503	60	-1,842	-1,636	-2,027	-1,124	-1,376	-1,513	-726	-902	-1,327	-1,044	-1,163	-1,285	-1,761	-3,037	-3,783	-2,907	-2,455	-1,716	-1,135	-947	-1,434	-884	-884	-1,340	-337	-333	-1,322	-242	-661	-661	-135	-135	-135	-135
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Gross Profit	85,700	88,521	87,537	75,420	49,562	47,579	45,470	37,199	30,961	30,644	31,820	25,524	26,145	25,438	25,465	24,986	25,724	26,510	24,576	10,737	500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	489	489	0	0	0	0	0	0	-301	0	0	0	-180	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Income Before Tax	46,707	-38,021	48,512	37,313	33,008	26,007	28,245	17,459	12,813	14,072	15,900	9,882	8,724	11,737	10,393	11,036	8,405	14,239	11,410	-645	-14,500	-7,839	-5,965	-5,700	-5,388	-4,178	-3,880	-4,967	-4,163	-3,954	-4,569	-5,386	-5,815	-4,449	-4,559	-5,410	-3,490	-5,010	-3,198	-3,811	-1,355	-5,912	-3,144	-77	-77	-2,622	-289	-1,089	-2,352	-1,128	-1,394	-1,517	-729	-904	-1,329	-1,045	-1,162	-1,287	-1,762	-3,031	-3,748	-2,855	-2,377	-1,584	-945	-734	-1,208	-741	-741	-1,321	-333	0	0	0	0	-	0	-	-	-
Income Tax Expense	11,863	-7,257	10,750	7,745	7,537	3,259	6,626	4,218	3,504	3,743	3,719	2,219	-2,713	-31,603	613	610	476	608	450	-14	-12	0	-8	0	-7	0	-210	397	-119	107	-153	-733	-396	-522	-343	1,180	-418	901	208	303	-1,352	2,666	490	-1,429	0	1,338	-778	-276	-1,517	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	333	1,322	242	661	661	135	135	135	135
Interest Expense	1,704	0	0	-1,704	2,822	905	324	93	0	0	0	0	336	0	0	336	399	393	450	343	344	344	371	234	124	129	91	110	44	67	93	118	13	47	5	62	22	6	16	33	22	10	9	10	0	3	1	1	2	3	3	2	3	4	5	5	8	6	7	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	336	399	393	450	343	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Net Income	34,844	-30,764	37,762	29,568	25,471	22,748	21,619	13,241	9,309	10,329	12,181	7,663	11,437	43,340	9,780	10,426	7,930	13,630	10,960	-645	-14,500	-7,839	-5,965	-5,700	-5,388	-4,178	-3,880	-4,967	-4,163	-3,954	-4,569	-5,386	-5,815	-4,449	-4,559	-5,410	-3,490	-5,010	-3,198	-3,811	-1,355	-5,912	-3,144	-77	-77	-2,622	-289	-1,089	-2,352	-1,128	-1,394	-1,517	-729	-904	-1,329	-1,045	-1,162	-1,287	-1,762	-3,031	-3,748	-2,855	-2,377	-1,584	-945	-734	-1,208	-741	-741	-1,321	-333	-333	-1,322	-242	-661	-661	-135	-135	-135	-135
Net Income Applicable To Common Shares	0	0	37,762	29,568	25,471	22,748	21,619	13,241	9,309	10,329	12,181	7,663	11,437	43,340	9,780	10,426	7,930	13,630	10,960	-645	-14,500	-7,839	-5,965	-5,700	-5,388	-4,178	-3,880	-4,967	-4,163	-3,954	-4,569	-5,386	-5,815	-4,449	-4,559	-5,410	-3,490	-5,010	-3,198	-3,811	-1,355	-5,912	-3,144	-1,744	-77	-2,622	-289	-1,089	0	-1,128	-1,394	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Net Income From Continuing Ops	34,844	-30,764	37,762	29,568	25,471	22,748	21,619	13,241	9,309	10,329	12,181	7,663	11,437	43,340	9,780	10,426	7,930	13,630	10,960	-645	-14,500	-7,839	-5,965	-5,700	-5,388	-4,178	-3,880	-4,967	-4,163	-3,954	-4,569	-5,386	-5,815	-4,449	-4,559	-5,410	-3,490	-5,010	-3,198	-3,811	-1,355	-5,912	-3,144	-1,744	-77	-2,622	-289	-1,089	0	-1,128	-1,394	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Net Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	336	399	393	450	343	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Non Operating Income Net Other	0	0	0	1,704	2,207	905	-324	93	71	68	62	81	0	34	111	336	399	393	450	343	344	344	371	234	124	129	301	-287	151	-40	246	851	377	568	339	-1,118	494	-901	-208	-303	1,352	-2,666	-490	-39	1,429	-1,338	778	276	0	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Operating Income	41,692	-37,188	46,699	35,609	30,801	25,102	28,569	17,366	12,742	14,004	15,838	9,801	8,618	11,704	10,282	10,700	8,007	13,845	10,959	-988	-14,843	-8,183	-6,336	-5,933	-5,512	-4,307	-4,181	-4,680	-4,314	-3,914	-4,814	-6,238	-6,192	-5,017	-4,897	-4,292	-3,984	-4,109	-2,990	-3,508	-2,707	-3,246	-2,654	-1,505	-1,505	-1,284	-1,067	-1,365	-2,034	-1,131	-1,397	-1,519	-732	-908	-1,333	-1,050	-1,170	-1,292	-1,769	-3,045	-3,791	-2,915	-2,464	-1,724	-1,143	-950	-1,437	-885	-885	-1,342	-337	-333	-1,322	-242	-661	-661	-135	-135	-135	-135
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Other Operating Expenses	68,876	139,876	52,883	49,757	29,956	32,142	24,544	25,723	25,567	21,950	20,527	20,404	22,397	17,613	19,323	18,437	22,116	17,052	17,879	13,436	15,343	8,183	6,336	5,933	5,512	4,307	4,181	4,680	4,314	3,914	4,814	6,238	6,192	5,017	4,897	4,292	3,984	4,109	2,990	3,508	2,707	3,246	2,654	1,505	1,505	1,284	1,067	1,365	2,034	1,131	1,397	1,519	1,221	908	1,333	1,050	1,170	1,292	1,769	3,045	3,791	2,915	2,464	1,724	1,143	950	1,437	885	885	1,342	337	333	1,322	242	661	661	135	135	135	135
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Reconciled Depreciation	9,143	8,568	8,570	6,531	615	553	37	34	33	31	31	97	31	89	688	77	271	7	6	14	12	9	8	8	7	13	13	13	12	9	9	13	6	11	9	8	8	7	6	5	6	6	6	3	3	3	3	3	8	7	21	6	6	6	6	7	7	7	8	8	8	8	8	8	8	3	3	1	1	2	0	-	0	-	-	-	0	-	-	-
Research Development	1,972	83,662	3,954	3,562	4,093	8,310	3,983	3,403	4,992	4,487	4,450	3,007	4,175	3,749	4,350	4,223	6,308	4,597	4,629	3,308	8,417	4,538	3,705	3,259	3,405	2,705	2,452	2,814	2,821	2,494	2,509	3,546	3,832	3,043	2,578	2,350	2,384	2,886	2,099	2,749	2,068	2,804	2,132	745	745	655	533	727	960	614	906	904	569	500	798	440	548	851	1,376	2,323	3,272	2,452	1,902	1,084	722	503	1,003	321	321	235	216	163	225	127	979	-	378	-	-	-
Selling And Marketing Expenses	28,932	21,681	18,312	17,764	7,827	7,584	7,268	6,790	7,974	6,521	5,981	5,676	6,563	5,579	5,622	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,664	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Selling General Administrative	13,104	11,879	10,084	11,954	6,841	6,583	5,650	9,640	5,253	5,632	5,551	7,040	6,790	4,406	5,212	10,063	11,409	8,068	8,988	8,416	6,926	3,644	2,631	2,674	2,107	1,602	1,730	1,866	1,494	1,420	2,306	2,691	2,360	1,975	2,320	1,942	1,600	1,223	891	760	639	441	521	761	761	629	535	637	1,074	517	492	615	652	408	535	611	622	441	393	722	2,184	463	562	640	421	447	434	564	564	1,340	356	317	261	233	1,327	-	543	-	-	-
Tax Provision	11,863	-7,257	10,750	7,745	7,537	3,259	6,626	4,218	3,504	3,743	3,719	2,219	-2,713	-31,603	613	610	476	608	450	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-	0	-	-	-
Total Operating Expenses	44,008	125,709	40,838	39,811	18,761	22,477	16,901	19,833	18,219	16,640	15,982	15,723	17,527	13,734	15,183	14,286	17,718	12,665	13,617	11,724	15,343	8,183	6,336	5,933	5,512	4,307	4,181	4,680	4,314	3,914	4,814	6,238	6,192	5,017	4,897	4,292	3,984	4,109	2,990	3,508	2,707	3,246	2,654	1,505	1,505	1,284	1,067	1,365	2,034	1,131	1,397	1,519	1,221	908	1,333	1,050	1,170	1,292	1,769	3,045	3,791	2,915	2,464	1,724	1,143	950	1,437	885	885	1,342	337	-333	-1,322	-242	-661	-661	-135	-135	-135	-135
Total Other Income Expense Net	5,015	-833	1,813	1,704	2,207	905	-324	93	71	68	62	81	106	34	111	336	399	393	450	343	344	344	371	234	124	129	301	-287	151	-40	246	851	377	568	339	-1,118	548	-907	-224	-336	1,330	-2,677	-499	1,419	1,419	-1,341	777	274	-318	3	3	2	3	4	5	5	8	6	7	13	44	59	86	140	198	216	229	144	0	21	4	0	0	0	0	-	0	-	-	-
Total Revenue	110,568	102,688	99,582	85,366	60,757	57,244	53,113	43,089	38,309	35,954	36,365	30,205	31,015	29,317	29,605	29,136	30,123	30,897	28,838	12,448	500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	489	489	0	0	0	0	0	0	-301	0	0	0	-180	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	398,204
Cost of Revenue	-84,532
Gross Profit	313,672	313,672

Operating Income (+$)
Gross Profit	313,672
Operating Expense	-226,860
Operating Income	86,812	86,812

Operating Expense (+$)
Research Development	93,150
Selling General Administrative	47,021
Selling And Marketing Expenses	86,689
Operating Expense	226,860	226,860

Net Interest Income (+$)
Interest Income	0
Interest Expense	-0
Other Finance Cost	-0
Net Interest Income	0

Pretax Income (+$)
Operating Income	86,812
Net Interest Income	0
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	94,511	79,113 EBIT - interestExpense = 86,812 94,511 71,410
Interest Expense	0
Earnings Before Interest and Taxes (EBIT)	86,812	94,511
Earnings Before Interest and Taxes (EBITDA)	119,955

After tax Income (+$)
Income Before Tax	94,511
Tax Provision	-18,775
Net Income From Continuing Ops	62,037	75,736
Net Income	71,410
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	311,392
Total Other Income/Expenses Net	7,699	0

Technical Analysis of Catalyst Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Catalyst Pharmaceuticals Inc. The general trend of Catalyst Pharmaceuticals Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Catalyst Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (57.1%)		Bearish trend (-57.1%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Catalyst Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 14.97 < 17.40 < 17.43.

The bearish price targets are: 13.12 > 13.00 > 12.27.

Tweet this

Catalyst Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Catalyst Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending up: The MA 50 is trending up. +1
Close < MA 50: The price is below the MA 50. -1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close > MA 100: The price is above the MA 100. +1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Catalyst Pharmaceuticals Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Catalyst Pharmaceuticals Inc. The current macd is -0.14648126.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Catalyst Pharmaceuticals Inc price going down in the near term. -2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Catalyst Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Catalyst Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1

Catalyst Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Catalyst Pharmaceuticals Inc. The current adx is 15.80.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Catalyst Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1

Catalyst Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Catalyst Pharmaceuticals Inc. The current sar is 16.11.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Catalyst Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Catalyst Pharmaceuticals Inc. The current rsi is 45.75. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
Trending up: The RSI is trending up. +1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Catalyst Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Catalyst Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Catalyst Pharmaceuticals Inc price going up in the near term. +2
Trending up: The STOCH %K is trending up. +1

Catalyst Pharmaceuticals Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Catalyst Pharmaceuticals Inc. The current cci is -118.62019989.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1

Catalyst Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Catalyst Pharmaceuticals Inc. The current cmo is -11.37825327.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Catalyst Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Catalyst Pharmaceuticals Inc. The current willr is -74.34210526.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Catalyst Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Catalyst Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Catalyst Pharmaceuticals Inc. The current atr is 0.60477825.

Catalyst Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Catalyst Pharmaceuticals Inc. The current obv is 69,430,047.

Catalyst Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Catalyst Pharmaceuticals Inc. The current mfi is 35.03.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Catalyst Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Catalyst Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-05	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2023-12-06	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-07	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-08	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-12	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2023-12-13	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-15	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-21	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-29	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-03	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-09	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-11	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-17	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-19	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-22	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-23	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-25	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-30	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-31	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-02	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-02-09	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-15	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-02-16	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-20	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-26	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-29	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-03-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-05	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-03-06	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-03-07	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-03-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-20	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-21	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-22	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-01	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-02	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-03	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-09	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-11	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-04-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-16	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-17	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-18	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-19	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-22	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-23	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-24	STOCH	SHORT EXIT		The %K line crosses above the %D line.

6.3. Candlestick Patterns

Catalyst Pharmaceuticals Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Catalyst Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	45.750
Ma 20	Greater than	Ma 50	15.478
Ma 50	Greater than	Ma 100	15.438
Ma 100	Greater than	Ma 200	15.119
Open	Greater than	Close	14.800
Total			3/5 (60.0%)

Create your own Symbol Scanner

Get notifications about Catalyst Pharmaceuticals Inc

I send you an email if I find something interesting about Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Catalyst Pharmaceuticals Inc together

Get notifications about Catalyst Pharmaceuticals Inc

Quick analysis of Catalyst Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Catalyst Pharmaceuticals Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Catalyst Pharmaceuticals Inc (5 min.)

$15.12

$3.29

$-119.60 - $53.38

$-116.31 - $56.67

2. Growth of Catalyst Pharmaceuticals Inc (5 min.)

Is Catalyst Pharmaceuticals Inc growing?

How much money is Catalyst Pharmaceuticals Inc making?

How much money comes from the company's main activities?

3. Financial Health of Catalyst Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Catalyst Pharmaceuticals Inc? (5 min.)

What can you expect buying and holding a share of Catalyst Pharmaceuticals Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Catalyst Pharmaceuticals Inc

About Catalyst Pharmaceuticals Inc

Financial Health

Valuation

1.1. Profitability of Catalyst Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Catalyst Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Catalyst Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Catalyst Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Catalyst Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Catalyst Pharmaceuticals Inc
Buy, Hold or Sell?